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Scope of this thesis
Estrogen receptor signalling,…
 The estrogen receptor is a nuclear hormone receptor that is activated by estrogens. 
The activated receptor dimerizes and binds to responsive elements on the DNA. Cofactors 
are recruited to regulate the transcription of genes.  Thereby, estrogens can induce cell 
proliferation. 
…breast cancer…
 The clinic makes clever use of this characteristic in breast cancer treatment. In about 
70% of all breast cancer cases, the tumor expresses the estrogen receptor. Patients diagnosed 
with this type of breast cancer commonly receive endocrine treatment after surgical removal 
of the tumor. Endocrine treatment can either target the receptor with competitive drugs 
(antiestrogens), or prevent formation of natural estrogens by inhibiting the aromatase 
enzyme (aromatase inhibitors). Because such tumors are dependent on estrogens for their 
growth, both treatment modalities should result in growth arrest and prevention of disease 
recurrence.
…and endocrine resistance
 Endocrine treatment in breast cancer is often successful, yet a subset of patients 
develop therapeutic resistance. This thesis focuses on one type of endocrine resistance: the 
widely used antiestrogen tamoxifen. A number of factors have been attributed to tamoxifen 
resistance, among which phosphorylation of the estrogen receptor.
 A general introduction into the role of phosphorylation of ERα in tamoxifen resistance 
is given in Chapter 1. In this review, biological and clinical data are discussed concerning known 
and putative phosphorylation sites of ERα. Phosphorylation is the addition of a phosphate 
group onto a protein, which is a bulky and negatively charged molecule. Phosphorylation 
can affect the structural conformation of the receptor. This can in turn influence ER function, 
e.g. by interfering with dimerization or by differential recruitment of coregulators. Kinases 
and molecular pathways involved in targeting these sites are briefly discussed. Some 
phosphorylation events are beneficial to tamoxifen response, whereas others may induce 
resistance. 
 Chapter 2 addresses a more fundamental question of how different structural 
domains of the estrogen receptor define its function. This was done by a comparison between 
the two receptor subtypes: ERα and ERβ. Both proteins contain two activation function 
domains, AF-1 and AF-2, separated by a hinge region. Although both are members of one 
family and are partially conserved, their differences result in different function. By swapping 
domains between ERα and ERβ, we discovered that the synergy between the AF-1 and AF-2 
domains is dependent on the hinge region. Together, the domains determine the quantitative 
response to estradiol or tamoxifen.
 The estrogen receptor requires coregulators to perform its transactivation function 
on DNA. By differential coregulator recruitment it determines which genes are transcribed 
and which are blocked. In Chapter 3 we applied a high-throughput chip containing coregulator 
motif peptides, to investigate coregulator binding by full-length ERα. This technique enabled 
us to study both overexpressed and endogenous proteins in lysates from different cell lines. 
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Moreover, peptide binding was measured in crude lysates from patient tumor tissue.
 Phosphorylation of the estrogen receptor can affect its function by altering coregulator 
recruitment. Therefore, we investigated if protein kinase A (PKA) induced phosphorylation of 
the ERα Serine 305 residue, which has been associated with tamoxifen resistance, influences 
coregulator binding. Phosphorylation resulted in enhanced coregulator interactions.
 How does phosphorylation of ERα result in a conformational change and differential 
recruitment of coregulators ultimately lead to cell proliferation, tumor growth and tamoxifen 
resistance? Chapter 4 addresses these questions by genome wide analyses of the chromatin 
binding landscape and gene expression profile of cells expressing Serine 305 phosphorylated 
ERα. We discovered that one post-translational modification, i.e. ERα Ser305 phosphorylation, 
can dramatically influence the chromatin binding preferences of the receptor, here showing 
a strong enrichment at promotor start sites, 3’ and 5’ UTRs. We defined a 100-gene classifier, 
and determined distinct targets for the phosphorylated receptor, including MYC, a known 
oncogene. A differential regulation of the MYC pathway could very well explain resistance to 
tamoxifen. This suggestion is supported by the significant correlation of the classifier with poor 
disease outcome in two independent datasets of ERα positive, tamoxifen treated patients.
 Finally, Chapter 5 puts the work presented in this thesis in perspective and provides 
an outlook for future studies.
CHAPTER 1
review
A role for estrogen receptor phosphorylation 
in the resistance to tamoxifen
Renée de Leeuw, Jacques Neefjes, Rob Michalides
The Netherlands Cancer Institute, Dept. Cell Biology
International Journal of Breast Cancer 2011, Article ID 232435
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A role for estrogen receptor phosphorylation in the resistance to tamoxifen
Renée de Leeuw, Jacques Neefjes, and Rob Michalides
Abstract
 About two thirds of all human breast cancer cases are estrogen receptor positive. 
The drug of first choice for these patients is tamoxifen. However, about half of the recurrences 
after removal of the primary tumor are or become resistant to this drug. While many 
mechanisms have been identified for tamoxifen resistance in the lab, at present only a few 
have been translated to the clinic. This paper highlights the role in tamoxifen resistance of 
phosphorylation by different kinases on different sites of the estrogen receptor.We will discuss 
the molecular pathways and kinases that are involved in phosphorylation of ERα and how 
these affect tamoxifen resistance. Finally, we will elaborate on the clinical translation of these 
observations and the possibility to predict tamoxifen responses in patient tumor samples 
before treatment onset. The findings made originally on the bench may translate into a better 
and personalized treatment of breast cancer patients using an old and safe anticancer drug: 
tamoxifen.
1. Introduction
 Worldwide, some 1.5 million women are diagnosed with breast cancer annually. 
Approximately, 70% of human breast cancer expresses estrogen receptor alpha (ERα). 
These tumors are eligible to endocrine therapy. Over the last 30 years, tamoxifen has been 
the antiestrogen of first choice. However, about half of the recurrences in ER-positive breast 
cancer do not respond to tamoxifen, which is due to either acquired resistance or to intrinsic 
insensitivity to tamoxifen [1, 2]. From experimental studies, many different mechanisms have 
been suggested to explain resistance, including activation of kinase pathways or inactivation 
of pRb, that render the tumor cell independent of the ER pathway for its proliferation [2]. 
However, with exception of cErbB2 (neu) overexpression, which mostly, but not exclusively 
occurs in ERα-negative breast cancer [3, 4], currently none of the resistance mechanisms 
identified have been translated into clinical implementation. 
 It is evident that multiple factors are involved in tamoxifen resistance. Therefore, 
they should be examined together as an integrated set of predictive markers for diagnosis 
of individual patients. Not only the number of clinically relevant indicators for tamoxifen 
resistance is unknown, but also the proportion in which a particular marker contributes to 
resistance in patients is unclear. The relative contribution of these factors should be defined 
and potentially integrated into a combined set of predictive markers for tamoxifen responses 
of individual patients. 
 Tamoxifen stimulates the growth of osteoblasts, while it inhibits ERα-positive breast 
tumor cells. These two opposing effects of tamoxifen on cell growth can be explained by the 
fact that tamoxifen is a partial antagonist, acting as an agonist under particular conditions 
[5]. Tamoxifen resistance is usually due to a direct effect on ERα; tamoxifen may acquire 
agonistic properties for transactivation of ERα [6]. Therefore, a molecular understanding of 
the underlying mechanism of tamoxifen resistance could result in markers that specify how 
patients will respond to endocrine therapy. The potential translation of these markers into 
clinical evaluation has to be examined with historical material and ultimately in a prospective 
study. Identification of markers predicting the antibreast cancer response to tamoxifen would 
have major clinical implications. Currently, the clinical benefit of tamoxifen is similar to that 
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of aromatase inhibitors, although the side effects of the drugs markedly differ. Ultimately, by 
finding predictive markers, responsiveness to tamoxifen can be defined before treatment and 
patients will only receive tamoxifen if they are likely to benefit from it. And in case of resistance, 
patients may still respond to another treatment modality, such as aromatase inhibitors or the 
full antiestrogen antagonist, like fulvestrant, which may still be beneficial [5].
 The estrogen receptor superfamily consists of two homologous nuclear receptors: 
ERα and ERβ. ERβ is encoded by a different gene, and the two receptors exhibit different 
transcriptional activities and functions in breast cancer [7]. Because the phosphorylation of 
ERβ and a potential role in tamoxifen resistance have not been well characterised, we will not 
discuss this estrogen receptor subtype.
 In this chapter, we focus on phosphomodifications of ERα in tumor cells that, by 
themselves, do not affect the female hormone estradiol (E2) dependency of the tumor cells 
for proliferation, but could affect the response to tamoxifen. We will address the following 
questions: which phosphorylation sites are identified on ERα? How do these sites become 
phosphorylated? Which sites are associated with tamoxifen resistance? How does tamoxifen 
sensitivity become affected without any effect on E2 dependency? Which molecular pathways 
upstream or downstream of the phosphorylated ER are involved in this form of tamoxifen 
resistance? Which clinical data are in support of tamoxifen resistance due to phosphorylated 
ERα?
2. Effects of phosphorylation on the structure of ERα, which are relevant for tamoxifen resistance
 Phosphorylation of the estrogen receptor may change the 3-dimensional structure of 
the protein. Unfortunately, thus far no full-length ERα has been crystallised. This complicates 
characterisation of structural changes upon ligand binding or posttranslational modifications, 
such as phosphorylation. Furthermore, a conformational change due to phosphorylation 
could have consequences for the action of estrogens and antiestrogens. X-ray crystallography 
studies have thus far been performed on the ligand binding domain (LBD) of ERα. Estradiol 
binds to amino acids Glu353 from helix 3(H3), Arg394 from H5, and to His524 from H11 in the 
LBD of ER [8], whereas D351 in the LBD is critical for the interaction with the antiestrogen. 
Specific mutation of D351 into D351Y resulted in a receptor that shows an estrogenic, instead 
of an antiestrogenic, response to tamoxifen [9].
 Coactivators have a common signature motif, LXXLL, with which they can interact 
with ERα in a hormonedependent manner [10]. Whereas in a nonligand-bound state helix 
12 is highly mobile, upon binding of an agonist it takes a more fixed position, stabilising the 
conformation of ERα. Helix 12 forms a charge clamp with helix 3, creating a hydrophobic groove 
to which a coactivator can bind. In contrast, crystallography shows that, when an antagonist, 
such as tamoxifen, binds to the LBD, helix 12 itself occupies the coactivator binding site, 
rendering ERα inactive [11–13]. Structural changes of ER can influence coregulator binding and 
hence potentially the response to ligands.
 Besides binding to the LBD in the AF-2 domain, coactivators also bind to the AF-1 
domain of ERα, in a ligand-independent manner. Phosphorylation of sites within or outside 
the AF-1 region may affect the AF-1-dependent binding of cofactors as well.
 Phosphorylation of particular sites, especially of S118 and S305, affects the binding 
of coactivators in the presence of tamoxifen [14]. In case of S305, this is due to an altered 
conformation of ERα, which can be measured by fluorescence resonance energy transfer 
(FRET) [15]. In the presence of tamoxifen, S305 phosphorylation changes the orientation 
between ERα and coactivator SRC-1 [14]. This altered orientation renders ERα transcriptionally 
active in the presence of tamoxifen. An altered conformation of ERα due to phosphorylation 
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of S305 resulted in a tamoxifenresistant phenotype of ERα, not only measured by FRET, but 
also by biological assays [6, 16]. Not only tamoxifen but also arzoxifene is converted from an 
antagonist into an agonist after the S305 phosphorylation-induced conformational arrest of 
ERα [16]. These findings strongly suggest that subtle changes in the conformation of ERα 
upon binding to antiestrogens are at the basis of resistance to antiestrogens. This provides the 
framework to consider a role for phosphorylation of ERα in resistance to tamoxifen.
3. ERα phosphorylation sites with a putative role in tamoxifen resistance 
 Several kinase pathways have been associated with tamoxifen resistance, including 
activation of the protein kinase A (PKA) [17], mitogen-activated protein kinase (MAPK) [18] and 
p21-activated kinase-1 (PAK-1) signaling pathways [19]. These kinases induce phosphorylation 
of ERα or of its coregulators. This paper focuses on the phosphorylation sites on ERα that could 
contribute to an altered response to tamoxifen and on which kinase pathways and upstream 
activators are involved. A summary of the putative phosphorylation sites in ERα is presented 
in Figure 1 and Table 1. They are discussed separately below.
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Eects of phosphorylation on tamoxifen response:
Fig1: ERα phosphorylation involved in tamoxifen response
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Figure 1: ERα phosphorylation involved in tamoxifen response. From left to right: AF-1 domain, 
DNA-binding domain (DBD), hinge region, AF-2 domain, and F domain containing helix 12.
3.1. S102/S104/S106. 
 Serine residues S102, S104, and S106 at the N-terminal AF-1 region of ERα are 
phosphorylated by glycogen synthase kinase-3 (GSK-3) and by extracellular signal-regulated 
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kinases 1 and 2 (ERK1/2) and mitogenactivated protein kinase (MAPK) (=MEK1/2) pathways. 
These modifications lead to ligand-independent transcription of ERα and to an agonistic 
activity of tamoxifen [22, 23]. S102, a phosphorylation site discovered by mass spectrometry, 
requires concurrent phosphorylation of S104 [20]. ERα phosphorylation by GSK-3, which also 
targets S118, stabilizes ERα without ligand and modulates ERα transcriptional activity upon 
ligand binding. S104 and S106 can also be phosphorylated by the CDK2/cyclinA complex [24]. 
Cyclin A has been reported as a predictive marker for tamoxifen resistance in breast cancer 
patients [51].
Phosphosite Kinases Tamoxifen Reference
S46/47 PKC [22]
Y52 c-Abl [55]
S102/4/6 GSK-3, ERK1/2 MAPK, CDK2 resistance [20-23]
S118 CDK2, ERK1/2 MAPK, RAS/MAPK, GSK-3, CDK7, IKKa, mTOR/p70S6K dual effect [18, 25-30, 32-35]
S154 [22]
S167 ERK1/2 MAPK, p90RSK, CK2, Akt, mTOR/p70S6K sensitivity [25, 30, 33, 35, 37-41]
S212 [22]
Y219 c-Abl [55]
S236 PKA [17, 33]
S282 CK2 sensitivity [22, 42, 56]
S294 [22, 42]
S305 PKA, PAK1? resistance [15, 19, 33, 43-47, 51]
T311 RAS/MAPK [42, 55]
Y537 Src Y kinases dual effect [25, 33, 52-54]
S554 [22]
S559 CK2 [22, 56]
Table 1: Putative ERα phosphosites, the kinases that target them, and the effect on tamoxifen 
response.
3.2. S118. 
 Serine 118 is one of the most reported phosphorylation sites of ERα. It is targeted 
by a number of kinase pathways:MAPK, GSK-3, IKKα, CDK7, andmTOR/p70S6K. S118 
phosphorylation by MAPK increases binding of coactivator SRC3 [25] and renders ERα 
hypersensitive to estradiol [26]. Phosphorylated S118 decreases ERα affinity for tamoxifen and 
reduces binding to DNA, when ERα is tamoxifen bound [25]. In a tamoxifen-resistant cell line 
obtained by selection after prolonged exposure to tamoxifen, MAPK activity was found to be 
elevated and S118-P was increased [26]. Upstream, the RAS/MAPK pathway can be activated 
by IGF stimulation inducing phosphorylation of ERα S118 and resulting in ERα activation and 
enhanced response to estradiol [18]. Estradiol and EGF can induce the ERK1/2 MAPK pathway, 
which also leads to S118 phosphorylation of ERα [27]. Estrogen-dependent phosphorylation of 
S118-P can occur not only through the ERK1/2 MAPK pathway, but also by IKKα [28] and CDK7, 
a subunit of transcription factor II H [29].
 In MCF7 cells, the receptor tyrosine kinase RET mediates ERα phosphorylation 
at S118 and S167 via the mTOR/p70S6K pathway [30]. Activation of RET leads to estrogen-
independent transcriptional activation of ERdependent genes and resistance to tamoxifen, 
strongly suggesting that RET activity acts through the estrogen receptor. This hypothesis is 
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supported by a chromatin immunoprecipitation (ChIP) study on ERα and S118 mutants [52]. 
Phosphorylation of S118 influences the recruitment of coregulators to ERα-regulated genes 
pS2, c-myc, and cyclin D1 and affects E2-induced gene expression. The nonphosphorylatable 
S118A mutant has a greater impact on genes regulated through nonclassical mechanisms, 
such as ERα binding to fos/jun on an AP-1 promoter, than on estrogen responsive elements 
(ERE).
 The clinical relevance of S118 phosphorylation in tamoxifen resistance is still 
unresolved. On the one hand, S118-P has been associated with a more differentiated 
phenotype, good prognosis, and better response to tamoxifen [28], which is supported by 
other studies (see [31], Wigerup et al. unpublished data). Most importantly, these studies 
reported that the S118 phosphorylation had no effect on progression of disease or survival 
without tamoxifen treatment [31], thereby emphasizing that S118 phosphorylation is a clear 
predictive marker for response to tamoxifen in these studies.
 On the other hand, S118 phosphorylation was negatively correlated with response 
to endocrine therapy in patients in other studies [32–34]. Nontreated patients have a better 
prognosis when they are positive for S118-P in these studies [32, 33]. These results are not easily 
reconciled with the previously mentioned studies (see [28, 31], Wigerup et al. unpublished 
data). Besides differences in patient series and tumor types, it is not clear which kinase 
activities in the tumors are resulting in S118 phosphorylation. In patients, both MAPK and RET 
expressions are associated with poor response to antihormonal therapy [53]. Activation of 
the ERK1/2 MAPK pathway apparently results in S118 phosphorylation, but it also induces a 
bypassing of the ER pathway, thereby rendering tumors hormone-independent.
 CDK7-mediated phosphorylation is indicative of an active ERα. Whereas the MAPK 
mechanism may well be responsible for a worse outcome of disease, irrespective of tamoxifen 
treatment, the CDK7 mechanism would indicate a proper functioning of ERα, being an 
adequate target for tamoxifen treatment [33].
3.3. S167. 
 Serine 167 is phosphorylated by Akt, p90RSK, and mTOR/p70S6K. The latter kinase 
also phosphorylates S118. Akt is induced by EGF and IGF [35], p90RSK only by EGF stimulation 
[36]. EGFR overexpression induces S167 phosphorylation, increases binding of ERα to DNA, 
enhances the binding of coactivator SRC3 to ERα in the presence of E2, and consequently 
enhances transcription. Moreover, in vitro, S167-P reduces sensitivity to tamoxifen [25, 32]. 
Other kinases that target S167 include ERK1/2 MAPK [32, 37] and, upon E2 binding of ERα, 
casein kinase II (CK2) [38]. S167-P does not affect ligand binding [25].
 The clinical data of S167 phosphorylation are conflicting. In ERα-positive, tamoxifen-
treated patients, activated AKT (pAKT) is associated with high risk for relapse and decreased 
overall survival [39], which would imply that S167-P is associated with a worse disease outcome. 
However, it is important to realise that Akt, like ERK1/2 MAPK, has many other targets, which 
could well bypass the estrogen-receptordependent signaling.
 Notwithstanding, in a set of 75 primary breast carcinomas of patients with metastatic 
breast cancer who received first-line endocrine treatment after relapse, those staining high 
for S167-P relapsed later. The metastases responded well to endocrine treatment and S167-P 
correlated with longer survival after relapse. This implies that S167-P is a predictive marker for 
a good response to endocrine therapy [34, 37].
3.4. S282. 
 Serine 282 resides in the hinge region and, like S167, can be phosphorylated by CK2. 
Estradiol increases phosphorylation of S282, stabilizes ER, and induces transcriptional activity 
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[20]. In patients, low levels of S282 phosphorylation are associated with reduced overall 
survival in ER-positive breast tumors from tamoxifen-treated patients, suggesting that S282 
phosphorylation can be predictive for response to tamoxifen [40].
3.5. S305. 
 Serine 305 resides at the C-terminus of the hinge region that provides a centre of 
rotation to the total ERα. The region around Ser305 is a multifunctional domain that binds to 
many coregulatory proteins and is involved in the regulation of activity and stability of ERα 
[42]. Phosphorylation of Ser 305 occurs by protein kinase A and is associated with resistance to 
tamoxifen in patients (see [43–45],Wigerup et al. unpublished data). This domain also controls 
ERα ubiquitination and subsequent proteosomal degradation of ERα, that is influenced by 
ligands [46]. Different ligands can induce different conformations of ERα and hence affect 
accessibility to the hinge region for modifying proteins, such as ubiquitin ligases. This implies 
that ligands can be selective for specific posttranslational modifications. 
 Within the hinge region, lysines K302/303 are involved in proteasomal degradation of 
ERα by fulvestrant and are the targets of polyubiquitination. K302 and K303 are both required 
for monoubiquitination by the BRCA1/BARD1 E3 ligase of E2- or tamoxifen-bound ERα [54]. 
K303 is also target for acetylation (inhibiting ER activity) and for methylation (stabilizing ER 
and increasing activity), whereas S305 phosphorylation prevents acetylation of K303 [55], 
thereby stimulating ER activity. The reverse is also true: a K303R mutation is frequently found 
in breast cancer, which prevents acetylation and increases phosphorylation of Ser305 by PKA 
[56]. These findings indicate that the hinge region is affected by various posttranslational 
modifications that affect structure and functioning of ERα. Some of these modifications and 
their cross-talk are shown in Figure 2.
S282S294 S305 T311
AF-1 DBD hinge AF-2













Figure 2: Posttranslational modifications in the ERα hinge region. S305 phosphorylation prevents 
acetylation of K302/303. The natural K303R mutation blocks K302/303 acetylation and stimulates
S305 phosphorylation.
 Besides PKA, p21-associated kinase 1 (PAK1) has been suggested as an upstream 
kinase involved in the phosphorylation of Ser305. PAK1 phosphorylation of ERα S305 can lead 
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to a secondary event on S118, presumably due to a conformational change of the estrogen 
receptor [15, 19]. PAK1 overexpression by itself is associated with resistance to tamoxifen in 
vitro [19] as well as in patients [32, 44, 45, 47]. Notably, in an experimental tamoxifenresistant
setting, tamoxifen induces PAK1, maintaining ERα in the tamoxifen-insensitive state [19]. The 
evidence that PAK1 phosphorylates S305 [19] was indirect and was not confirmed by a direct 
inspection of the phosphorylation of ERα Ser305 using specific antibodies or by the introduction 
of a dominant-active PAK1 into breast cancer cells [44]. Moreover, overexpression of PAK1 was 
not correlated with S305 phosphorylation in two different studies on breast cancer, indicating 
that these two events are independent (see [44], Wigerup et al. unpublished data). PKA 
phosphorylates S305, keeping ER in an active conformation when tamoxifen is bound, which 
means that it mimics an estrogen-bound ER [15]. This was not observed with overexpression 
of PAK1 [44].
 Clinical studies show that tamoxifen resistance occurred in endocrine-treated patients 
with detectable S305-P in the primary human breast tumor [44]. Since S305 phosphorylation 
has no effect on patients that were not endocrine treated, this Ser305P markers appears to 
be a predictive marker for treatment outcome and not for general disease progression [43]. A 
combination of PAK-1, phosho-PKA, a marker of activated PKA, and the phosphorylated S305
marker identified approximately 60–70% of all tamoxifen resistant cases in breast cancer. This 
occurred in series of breast cancer from premenopausal and postmenopausal patients, in early 
to advanced stages of disease, indicating that the marker is independent of clinical stage of 
disease and of the hormonal status of the patient (see [31, 43, 45],Wigerup et al. unpublished 
data).
3.6. Y537. 
 Tyrosine 537 is phosphorylated by the Src family tyrosine kinases. Phosphorylation of 
this tyrosine inhibits ER dimerisation and estrogen binding and reduces transcriptional activity 
of ERα [48]. Tyr 537 is located at the N-terminus of helix 12, and mutation of this Tyr into a 
nonphosphorylatable alanine facilitates the rotation of helix 12 into an active conformation 
of ERα in the absence of any ligand [49]. Phosphorylation by activated Src increases affinity 
for E2 and decreases affinity for tamoxifen [25]. Nonphosphorylatable mutants show ligand 
independent transactivation, but this is inhibited by tamoxifen [32]. There is no apparent 
clinical evidence that Y537 phosphorylation influences tamoxifen response in patients. Of 
note, a naturally, but rarely occurring, Y537 mutation to asparagine (Y537N) in breast cancer 
metastasis constitutively activates the estrogen receptor by a conformational change of helix 
12, which may contribute to breast cancer progression and resistance to endocrine treatment
[50].
4. Other ERα phosphorylation sites with no (known) role in tam oxifen resistance
 Several other phosphorylation sites of ERα have been found, which have not been 
associated with tamoxifen, either since tamoxifen was not included in the studies or because 
the phosphosite has not been included in clinical studies on tamoxifen resistance. These sites 
are briefly discussed below.
4.1. S46/47. 
 Ser-46/47 phosphorylation plays a role in ligand-dependent activation of ERα. 
Mutation of Ser-46/47 or Ser-294 to alanine markedly reduced estradiol-dependent reporter 
activation. S47 phosphorylation may influence other posttranslational modifications of ERα. 
S46 is a putative recognition site for protein kinase C and seems to hold a predominant effect 
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on transcriptional activity, rendering S47 phosphorylation a “bystander” effect [20].
4.2. Y52 and Y219. 
 Tyrosine 52 and 219 are phosphorylated by c-Abl, a Src-like nonreceptor tyrosine 
kinase. Y219 phosphorylation affects ER dimerization and DNA binding. This results in 
enhanced ERα transcriptional activity, both in absence and presence of estradiol. Stabilisation 
of ERα through c-Abl ultimately leads to proliferation and invasion of breast tumor cells [21].
4.3. S154, S212, S294, and S554. 
 Serine 154, 212, 294, and 554 are putative ERα phosphorylation sites discovered 
by mass spectrometry on phosphopeptides [20]. In vitro, an alanine mutation of S294 
reduces estradiol-dependent transcription [20], suggesting that S294 phosphorylation 
is needed for a functional ER. Furthermore, S294 phosphorylation has been detected by 
immunohistochemistry (IHC) in human breast carcinoma but no significant effect of S294-P 
on tamoxifen response in terms of recurrence or overall survival has been observed [40]. The 
biological relevance of the other three serines remains to be tested.
4.4. S236. 
 Serine 236 is located in the DNA binding domain (DBD). It is phosphorylated by PKA, 
upon which ER dimerisation and DNA binding in the absence of ligands are lost, rendering ER 
transcriptionally inactive [32], but both estradiol and tamoxifen can overcome this inhibition
[17]. This would imply that S236-P in itself has no effect on tamoxifen sensitivity.
4.5. T311. 
 Threonine 311 is the only known threonine phosphorylation site on ERα. An active 
RAS/MAPK pathway stimulates ERα phosphorylation at Thr-311 [21]. Phosphorylation of T311 
can be detected by immunohistochemistry, but thus far has not been significantly associated 
with altered tamoxifen sensitivity in breast cancer patients [40].
4.6. S559. 
 Serine 559, like Y537, resides in the F domain of the estrogen receptor, in helix 12. This is 
of particular interest, because the position of helix 12 determines interaction with coactivators 
and corepressors and regulates response to (ant)agonists. Therefore, S559 phosphorylation 
can probably influence ER binding to coregulators, such as SRC-1, by changing the position 
of helix 12 and as a consequence the response to ER ligands. S559 is targeted by CK2 [20]. 
Phosphorylation inhibits ligand-independent activation of ERα. ERα is phosphorylated at S559 
in human breast carcinoma biopsies [41].
5.Main points, side-issues and interrelated affairs
 We presented, thus far, the effects of phosphorylation of relevant sites in ERα as single 
events. Of course, reality is more complex and modifications not only occur on ERα itself, but 
also take place on the associated cofactors and on targets outside the ERα signaling pathways 
that could have an effect on ERα-mediated signaling. Three examples below illustrate this 
point.
(a)  Phosphorylation of CARM1, an arginine methyltransferase, by PKA [57]. 
Phosphorylation of CARM1 by PKA enhances its interaction with S448 in the LBD of ERα 
and creates a novel, more firm platformfor binding of other cofactors. The net result is 
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tamoxifen resistance by the buildup of a PKA-specific coactivator complex. Because 
the arginine methyltransferase CARM1 is involved in methylation of histones H3 andH4 
that is crucial for transcription to occur, the ERα-phosphoCARM1 complex provides a 
specific regulatory unit for transcription. Still, additional events are needed for tamoxifen 
resistance, among which possibly the phosphorylation of ERα S305 by PKA.
(b) PAK1 phosphorylates an alternate, but in breast cancer frequently present, isoform of 
the SRC3 steroid-receptor cofactor (SRC3-3δ4), allowing it to bridge between EGF-R and 
FAK1 (focal adhesion kinase 1) and thereby activating ERK1/2 MAPK [58]. Activation of 
this pathway possibly renders breast tumor cells tamoxifen resistant. This provides a novel 
turn to the role of PAK1 overexpression in breast cancer.
(c) The selective activity of SRC-3 depends on specific phosphorylation of SRC3 [59]. SRC3 
has six specific phosphorylation sites targeted by multiple kinases. These phosphorylated 
sites determine the optimal of SRC3 [59]. SRC3 has six specific phosphorylation sites 
targeted by multiple kinases. These phosphorylated sites determine the optimal 
interaction with other transcription factors and are required for different physiological 
functions.
 These three examples demonstrate that there is a complex interrelated network 
of regulatory circuits influencing ER transcriptional activity and that, by modification of one 
circuit, other circuits are affected. They also indicate that one particular mode of modification 
can have multiple effects. Most of the studies have addressed only one significant mode 
of action, but it is evident that many factors can play a role in the resistance to endocrine 
treatment.
6. Downstream signaling / gene expression / pathways
 How does phosphorylation of ERα affect resistance to tamoxifen? The estrogen 
receptor is a nuclear receptor, which binds to specific sequences in the DNA and regulates 
the expression of ER-dependent genes. Phosphorylation of ERα can affect DNA binding, 
for example, by inhibiting dimerization of the receptor, and can influence ERα activity by 
changing the binding to coactivators or the orientation of components of the transcription 
factor complex. Which genes are then affected? In the classical way, an estradiolbound 
estrogen receptor dimerizes, binds to an estrogen responsive element (ERE), and transcribes 
the gene that lies within its proximity. The estrogen receptor can also regulate transcription 
of genes in an indirect manner, by binding to other transcription factors: AP-1, SP-1 [60], or 
activated NFkB [61]. When these interactions occur, transcription of the AP-1-, SP-1-, or NFkB-
dependent genes becomes also dependent on ERα. When tamoxifen is bound to ERα, the 
classical estrogen responsive genes are not expressed but tamoxifen-bound ERα has its own, 
different transcriptome, most likely generated through the nonclassical pathway [62, 63].
 Different kinase pathways can be activated chemically in cells by adding growth 
factors (EGF or IGF) or cAMP, which induces PKA. This approach was used in a gene expression
study on MCF7 breast cancer cells [64]. Kinases were activated, and gene expression profiles 
were compared in the presence or absence of tamoxifen. Tamoxifen treatment resulted in 
differential gene expression with either growth factor stimulation or PKA activation.Which of 
these genes is essential for tamoxifen resistance remains a crucial question.
 A more complete, but also more complex, picture arises from microarray analyses 
performed in tumors of tamoxifentreated ERα-positive breast cancer patients. Frasor et al. 
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described a set of genes associated with disease recurrence, a subset of which is associated 
with treatment with tamoxifen [63]. Loi et al. applied gene expression profiling in a similar way. 
They developed a gene classifier to predict clinical outcome in tamoxifen-treated ERα-positive 
breast cancer patients. This classifier contains genes involved in invasion (SLIT2 and RECK), 
anti-inflammatory response (TGFBR4, PTGER4, C3, and GNG2), and cell cycle regulation [65]. 
In later studies, this group validated a number of hits by qPCR and hence demonstrated that 
EZH2 downregulation is associated with a favourable outcome [66] and that downregulation 
of SIAH2, an E3-ubiquitin ligase, would imply tamoxifen resistance [67]. They also showed 
that an extracellular matrix cluster of genes (TIMP3, FN1, LOX, and SPARC) is associated with 
tamoxifen resistance [68]. In any of these studies, it is unclear whether phosphorylation of the 
estrogen receptor plays a role in tamoxifen resistance in these patients. Looking at multiple 
genes, instead of only one, could be more informative for treatment outcome. Therefore, Kok 
et al. compared three gene classifiers [69–71] for tamoxifen. This comparison indicates that a 
multigene approach would improve the prediction of response to tamoxifen [31].
 There is as of yet only one microarray study on tamoxifen-treated ERα-positive 
human breast cancers that addresses a specific phosphorylation site, S305P, and the effect on 
gene expression. A pathway analysis highlighted several pathways being affected, including 
PKA, ERK1/2 MAPK, EGF signaling, CDK regulation, and interferon alpha signaling [44].
7. Discussion
 In total, 19 phosphorylation sites have been identified in ERα thus far, as summarized 
in Figure 1. Phosphorylation of S167, S118, S282, and Y537 is beneficial for tamoxifen response 
according to experimental and, for S167, S118 and S282, because of reported clinical data. 
Tamoxifen resistance is likely to occur when S104/S106 or S305 is phosphorylated. The 
contribution of phosphorylation of other target sites to tamoxifen resistance remains to be 
determined. Some of these phosphorylation sites have been shown with FRET technology 
to induce a conformational change of ERα, when exposed to other antiestrogens, such as 
fulvestrant and raloxifene [6]. Thereby, they may affect the antagonistic behavior of these 
compounds but the molecularmechanisms remain to be elucidated.
 Upstream of ERα, different kinase pathways are involved. Dependent on the pathway 
and the phosphorylation sites involved, tamoxifen response can be affected either directly 
through ERα modification or by activation of other signaling pathways. Phosphorylation of 
S118 is described as an example of this: an activated ERK1/2 MAPK pathway phosphorylates 
S118 but possibly induces tamoxifen resistance through the ERK1/2 MAPK pathway itself, 
rather than ER signaling. S118 phosphorylation by the ER-associated CDK7 indicates an 
activated ER which would imply a beneficial effect on tamoxifen treatment in patients.
 EGFR and cErbB2 can also affect ER signaling. Tamoxifen response may be restored 
by blocking EGFR with gefitinib [3, 72]. In a clinical study, blocking cErbB2 with trastuzumab 
restores ERα signaling in ERα-positive tumors and improves response to the aromatase 
inhibitor letrozole [73]. This would suggest a better response to tamoxifen as well.
 It is challenging to extrapolate experimental data from ER activation to the clinic 
and vice versa. In in vitro studies, it is feasible to examine differential gene expression after 
treatment and compare the profile before and after treatment, or in absence or presence of 
phosphorylation. Translation of this information to the clinic can, however, be troublesome, 
since adjuvant tamoxifen treatment is started after surgical removal of the primary tumor. The 
in vitro experiments measure gene expression changes associated with acquired resistance, 
whereas investigation of primary tumors that respond better to treatment highlights genes 
which play a role in intrinsic resistance to tamoxifen. Because primary tumors have not been 
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exposed to tamoxifen, endocrine treatment cannot be a selective factor for these resistance 
markers. They may occur at random during normal tumor development or may well coincide 
with other tumor progression markers. For example, overexpression of cErbB2 or of EGFR in 
breast cancer marks worse course of disease not only in ERα-negative, but also in ERα-positive
tumors and is a marker for tamoxifen resistance as well [74].
 Phosphorylation of Ser305 is a marker for intrinsic resistance to tamoxifen. It is not 
associated with disease progression in the absence of tamoxifen treatment [44]. It is also a 
marker for the choice of treatment, since a combination of S305-P, S118-P, and overexpression 
of SRC-1 or cyclin D1 coactivators dictates resistance to different antiestrogens [14, 15]. Since 
outgrowth of micrometastases into tamoxifen resistant tumors occurs over longer periods of 
time (up to 15 years), extra alterations in the micrometastases outgrowths, in addition to the 
S305 phosphorylation status, potentially influence tamoxifen resistance. Phosphorylation of 
Ser305, however, was still maintained in the few metastases samples that could be examined 
[44]. Alternatively, one could study acquired and intrinsic resistance during neoadjuvant 
treatment with antiestrogens, where patients are treated up to three months prior to the 
surgical removal of the primary tumor. Hence, samples can be obtained before and after 
treatment for comparison [75]. In another study by this group, activation of the ERK1/2/MAPK 
pathway was a major factor associated with acquired resistance to tamoxifen [74].
 Phosphorylation of S305 has experimentally been linked to resistance to tamoxifen, 
because of an altered conformation of ER, where tamoxifen behaves as an agonist in FRET and 
expression reporter assays [15]. In patients, S305-P was associated with alterations in the PKA 
pathway that result in stimulation of PKA activity [15, 44]. Also experimental enhancement 
of PKA activity in breast tumor cells led to proliferation of T47D breast tumor cells in the 
presence of tamoxifen [15]. It is, however, still possible that S305P is a marker for tamoxifen 
resistance without any direct involvement. It could merely mark PKA related events that 
bypass the estrogen receptor and hence induce tamoxifen resistance. The altered orientation 
of components of the transcription factor complex and the conformational changes in ERα 
strongly suggest, but are no proof of, a direct involvement. S305-P is, however, one of the few 
selective markers that predict resistance to tamoxifen in breast cancer patients. Definition of 
the activation of relevant signaling pathways in the ERα-positive breast tumors (that constitute 
the bulk of human breast cancers) prior to endocrine treatment is essential for treatment 
success and will ultimately lead to personalised treatment of breast cancer patients.
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The hinge region of the human estrogen receptor determines 
functional synergy between AF-1 and AF-2 in the quantitative 
response to estradiol and tamoxifen
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Abstract
Human estrogen receptors α and β (ERα and ERβ) greatly differ in their target genes, 
transcriptional potency and cofactor-binding capacity, and are differentially expressed in 
various tissues. In classical estrogen response element (ERE)-mediated transactivation, ERβ 
has a markedly reduced activation potential compared with ERα; the mechanism underlying 
this difference is unclear. Here, we report that the binding of steroid receptor coactivator-1 
(SRC-1) to the AF-1 domain of ERα is essential but not sufficient to facilitate synergy between 
the AF-1 and AF-2 domains, which is required for a full agonistic response to estradiol (E2). 
Complete synergy is achieved through the distinct hinge domain of ERα, which enables 
combined action of the AF-1 and AF-2 domains. AF-1 of ERβ lacks the capacity to interact with 
SRC-1, which prevents hinge-mediated synergy between AF-1 and AF-2, thereby explaining 
the reduced E2-mediated transactivation of ERβ. Transactivation of ERβ by E2 requires only 
the AF-2 domain. A weak agonistic response to tamoxifen occurs for ERα, but not for ERβ, and 
depends on AF-1 and the hinge-region domain of ERα.
Introduction
 Estrogen receptors a and b (ERα and ERβ) are homologous members of the nuclear 
receptor superfamily and are encoded by two different genes. They control crucial processes in 
physiology and are prognostic markers in breast cancer; their expression determines whether 
or not endocrine treatment is given as an adjuvant therapy (Speirs et al., 2004). On binding 
of agonistic ligands, the DNA-bound receptor recruits cofactors, which enables the receptor 
to transmit its regulatory information to the cellular transcription complex, including RNA 
polymerase II (transactivation). ERα and ERβ mediate distinct profiles of gene expression 
(Chang et al., 2008; Williams et al., 2008). This is due to a combination of differential ligand 
response (Barkhem et al., 1998; Paech et al., 1997; Paige et al., 1999; Van Den Bemd et al., 
1999), distinct interaction with coactivators (Kraichely et al., 2000) and binding to specific 
estrogen response elements (EREs) (Klinge et al., 2004). Consequently, ERα and ERβ exert 
different effects on the organization, growth and differentiation of various tissues, including 
colon, uterus, bone, brain and mammary gland (Forster et al., 2004; Helguero et al., 2005; 
Kudwa et al., 2005; Wada-Hiraike et al., 2006b; Wada-Hiraike et al., 2006a). Transactivation 
of ERs can occur in two different ways. One is by classical ER transactivation, in which an ER 
homodimer binds to a palindromic ERE sequence (Klein-Hitpass et al., 1989). The other way 
is by non-classical transactivation, in which the ER is tethered to other transcription factors, 
including the Fos-Jun complex, NF-kB and Sp1, to render transcription of their genes responsive 
to ER activity (Pearce and Jordan, 2004; Sabbah et al., 1999). ERα and ERβ differ in their 
classical and non-classical transactivation by estradiol (E2) (Paech et al., 1997; Weatherman et 
al., 2001). These differences between ERα and ERβ are reflected in differences in their amino 
acid sequences and/or different interactions between the various domains of the receptor. 
ERα is composed of 595 amino acids, whereas ERβ is 530 amino acids. The N-terminal A/B 
domain (also known as the AF-1 domain) has a ligand-independent transactivation function 
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and has 17% amino acid homology between the ERs. The highly conserved central C region, 
with 96% homology, encompasses the DNA-binding domain (DBD). The flexible hinge, or D 
region, contains nuclear localization signal (NLS) information and links the C-domain to the 
multifunctional C-terminal E/F domain. The E/F domain (also known as the AF-2 domain) 
of the ERs shares 53% amino acid homology and contains the ligandbinding domain (LBD) 
and the ligand-dependent transactivation domain, including the cofactor-binding groove to 
which cofactor are recruited when the ER becomes activated. For ERα, it has been shown that 
interaction between the AF domains is essential for effective transactivation (Metivier et al., 
2001; Yi et al., 2002a).
 Despite similar in vitro ERE-binding capacities and comparable affinities for E2 
(Bowers et al., 2000; Yi et al., 2002b), human ERβ is considerably weaker than ERα with respect 
to ERE-dependent transactivation following E2 exposure (Yi et al., 2002b). Also, differences 
between human ERα and ERb have been reported for the non-classical pathway (Gustafsson, 
2000). The molecular mechanism underlying these differences in transcription by the ER 
subtypes is still unclear.
 The precise process of transactivation of genes by ERs is still unresolved. ER can 
dimerize and bind to its cofactors even when not bound to DNA, which occurs also in the absence 
of ligands (Carroll et al., 2006; Padron et al., 2007; Zwart et al., 2007a). For proper recruitment 
of RNA polymerase II, however, the ER needs to be bound to an ERE (Carroll et al., 2006; Sharp 
et al., 2006; Zwart et al., 2007a). Effective transactivation of ERα requires interaction between 
the N-terminal and C-terminal regions of ERα (Merot et al., 2004; Metivier et al., 2001), which 
is accomplished by the binding of ERα to cofactors (Metivier et al., 2001). The antiestrogen 
tamoxifen inhibits ERα-mediated transactivation by arresting the conformation of ERα such 
that the groove that interacts with the steroid receptor coactivator-1 (SRC-1) cofactor remains 
covered by the twelfth a helix of the LBD (Shiau et al., 1998). However, tamoxifen also has 
weak agonistic activity. This mild agonistic behavior can be enhanced by phosphorylation of 
serine 305 in the hinge region of ERα by protein kinase A (Michalides et al., 2004).
 Here, we investigate the differences between human ERα and ERβ with regard 
to E2-driven transactivation and the agonistic effect of tamoxifen. We show that a specific 
interaction of the AF-1 domain of ERα with SRC-1 is required, but by itself not sufficient, to 
induce a maximal response to E2. The maximal response to E2 demands, in addition, the 
hinge region of ERα. Human ERβ lacks an active AF-1 domain. The weak agonistic response 
to tamoxifen is dependent on the AF-1 domain of ERα, but also involves the hinge region of 
ERα for optimal transcriptional activity. The AF-1 domain of ERβ is not involved in tamoxifen-
mediated transactivation, explaining the differential response to the antiestrogen tamoxifen.
Results
Extent of transactivation by ER is dependent on the AF-1 domain
 ERα and ERβ differ mostly in their N-terminal AF-1 regions, which share 17% sequence 
homology and differ in size by 41 amino acids. We therefore examined the contribution of 
the AF-1 domains to optimal E2-driven transactivation. We generated swap mutants, in 
which AF-1 of ERα (amino acids 1-185) was replaced by the corresponding region of ERb 
(amino acids 1-144) and vice versa, resulting in ERαAF-1β and ERβAF-1α mutants (Fig. 1A). A 
detailed alignment of both AF-1 domains is shown in supplementary material Fig. S1. All four 
ER variants were analyzed for the extent of E2-induced transcription using an ERE-luciferase 
reporter construct with various concentrations of ligand (Fig. 1B). Maximal transactivation 
of ERα was considerably higher than that of ERβ, 47- versus 6-fold induction, respectively. 
Exchanging the AF-1 region of ERβ for that of ERα in ERβAF-1α greatly affected this response 
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and increased transactivation from 6- to 16-fold. Exchanging AF-1 of ERα for that of ERβ in 
ERαAF-1β, however, reduced transactivation from 47- to 6-fold, the level also reached by 
wild-type ERβ. These differences were not due to differences in RNA or protein levels, as has 
been determined by quantitative PCR (QPCR) analysis, western blot and luciferase reporter 
assays (supplementary material Fig. S2). The ERβAF-1 domain therefore reduces E2-induced 
transactivation, whereas the AF-1 domain of ERα is responsible for its enhancement, which is 
in agreement with a previous report (McInerney et al., 1998). Although exchange of AF-1 of 
ERβ for that of ERα in ERβAF-1α did increase maximal transactivation approximately threefold 
when compared with wildtype ERβ, the extent of transactivation did not match that of ERα. 
This suggests that additional features are involved in optimal E2-driven transactivation.
Fig. 1. Extent of transactivation 
by ER is dependent on the AF-1 
domain of ER. (A) Structural 
overview of ERα, ERβ and 
AF-1 swap mutants. (B) E2-
c o n c e n t r a t i o n - d e p e n d e n t 
transcription of an ERE-luciferase 
reporter. U2OS cells were 
transfected with ERα, ERβ, 
ERαAF-1β or ERβAF-1α (see key 
in A), co-transfected with the 
ERE-luciferase reporter gene and 
Renilla luciferase as the control. 
Cells were treated with 10–12, 10–11, 
10–10, 10–9, 10–8 M E2 for 36 hours 
or left untreated, and relative 
luciferase activity was measured. 
A representative experiment 
out of three independent 
experiments is shown. Error bars 
indicate standard deviation from 
duplicate samples. (C) The same 
conditions as in B were applied, 
but with 10–12, 10–11, 10–10, 10–9, 
10–8 M 4-OH-tamoxifen (TAM). (D) 
Luciferase signal for the tested ER 
variants under hormone-depleted 
conditions. Signals for all ER 
variants are related that of to 
ERα, which is set at 1. A representative experiment out of two independent experiments is shown. 
Error bars indicate standard deviation from duplicate samples. (E) Non-classical transactivation 
by ER is influenced by AF-1 of ERα. An AP-1–luciferase reporter assay was performed in U2OS 
cells, transfected with ER variants, the AP-1–luciferase reporter construct and Renilla luciferase 
as the control. Cells were treated with 10–8 M E2, 10–7 M tamoxifen or left untreated for 36 hours. 
Relative luciferase activity was measured and normalized using the Renilla signal. The relative 
luciferase signal for all ER variants was related to the CTS (charcoal-treated serum) value of ERα, 
which was set at 1. A representative experiment out of three independent tests is shown. Error 
bars indicate standard deviation from triplicate samples.
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 We then examined whether ligand-independent and tamoxifen associated 
transactivation are also linked to AF-1 of ERα. The AF-1 of ERα appeared responsible for 
the minor ligand-independent transactivation of ERα, because exchange of the AF-1 region 
between the ERs completely switched this ligand-independent behavior (see Fig. 1D). These 
results indicate that the AF-1 domain of ERα mediates ligand-independent transactivation, 
whereas such activity is not observed for the AF-1 domain of ERβ.
 Tamoxifen exhibits a weak agonistic effect on ERα activity (Michalides et al., 2004; 
Zwart et al., 2007b). We confirmed these data; transactivation by tamoxifen resulted in a 3.5-
fold enhancement over hormone-depleted conditions for ERα (see Fig. 1C). Neither ERβ nor 
the two swap mutants responded to tamoxifen, indicating that the weak response of ERα to 
tamoxifen is mediated by AF-1 of ERα. Because the ERβAF-1α construct, now containing AF-1 
of ERα, did not respond in an agonistic way to tamoxifen, additional features that are not 
conserved between the two ER isoforms are required for this response (see below).
 Our results indicated that AF-1 of ERα determines the extent of E2-mediated 
transactivation in a classical ERE-mediated transactivation assay. To investigate the role 
of AF-1 in a nonclassical transactivation reaction, we tested ERα, ERβ and the AF-1 swap 
mutants in an AP-1-driven luciferase assay (Fig. 1E). AP-1-mediated transcription by ERα and 
ERβAF-1α could be inhibited through E2 and not by tamoxifen. These features appeared to 
be AF-1 mediated, because ERβ and ERαAF-1β failed to respond. These data indicate that the 
discriminatory role of AF-1 between ERα and ERβ is not restricted to classical ERE-mediated 
transcription, but also applies to non-ERE, AP-1-dependent transactivation. 
The AF-1 domain of ERα, but not of ERβ, binds to SRC-1
 The AF-1 of ERα appeared to be responsible for efficient transactivation of ERα in 
a ligand-dependent and -independent manner, unlike AF-1 of ERβ, which lacks this activity. 
We next investigated whether this difference in transcriptional capacity correlated with the 
binding of these domains to the p160 coregulator SRC-1. SRC-1 binds to both the AF-1 and 
AF-2 domains of ERα; an interaction that generates a functional synergy between the two 
transactivation domains (Metivier et al., 2001; Webb et al., 1998). The Q-rich region of SRC-1 
binds AF-1 in ERα, whereas the consensus LxxLL-containing middle region of SRC-1 binds to 
the ligand-dependent AF-2 domain of ERα (Merot et al., 2004).
 We visualized these interactions in intact cells on a genuine ERE promoter sequence 
– the prolactin promoter-enhancer (PRL) region in HeLa cells. These cells contain a DNA 
array consisting of ~52 copies of stably transfected modified PRL (Sharp et al., 2006). The 
PRL array allowed visualization of a defined, ERE-containing DNA structure in the nucleus, to 
which ER and cofactors can be recruited. In addition, the size of this structure correlates with 
transcriptional activity of the ER-cofactor complex bound to this region (Hatzis and Talianidis, 
2002; Sharp et al., 2006; Zwart et al., 2007a). ERα, ERβ and both AF-1 swap mutants could 
recruit RNA polymerase II to the array structure under E2 conditions (see Fig. 2A-D). Under 
these conditions, the array structures were enlarged, which is associated with transcriptional 
activity. However, whereas ERα was capable of recruiting RNA polymerase II to the array under
hormone-depleted conditions, ERβ failed to do so. This difference in RNA polymerase II 
recruitment was associated with the AF-1 domain of ERα, because swapping this region to ERβ 
sufficed to enable RNA polymerase II recruitment under hormone-deprived conditions. This 
suggests that the AF-1 domain of ERα possesses ligand-independent transactivation activity, 
which is absent in ERβ, supporting the results of the transactivation studies presented in Fig. 1. 
We confirmed these interactions using truncation mutants of SRC-1 that bind only AF-1 or AF-
2. These truncation mutants of SRC-1 act as dominant-negative mutants over the endogenous
coactivators (Zwart et al., 2007a). One truncation mutant of SRC-1 (amino acids 1051-1240), 
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Fig. 2. RNA polymerase II 
recruitment by ER variants 
and AF-1-dependent SRC-
1 recruitment to PRL array 
structures. PRL arrays 
containing HeLa cells 
were transfected with ERα 
(A), ERβ (B) or AF-1 swap 
mutants (C,D) and treated 
with 10–6 M E2, tamoxifen 
or left untreated (CTS). 
Cells were fixed and 
stained with antibodies 
recognizing ERα or ERβ 
and RNA polymerase II. 
Arrowheads indicate the 
array structure, analyzed 
for the presence of the 
RNA polymerase II (close-
up shown in inset). Scale 
bars: 5 mm. (E) PRL arrays 
containing HeLa cells 
were transfected with 
one of the different ER 
constructs and treated 
with 10–6 M E2. Cells 
were then cotransfected 




Cells were fixed and 
stained with antibodies 
recognizing ERα or ERβ 
and RNA polymerase II. 
Arrowheads indicate the 
array structure, analyzed 
for the presence of the 
SRC-1-YFP fragment and 
RNA polymerase II (close-
up shown in inset). Scale 
bars: 5 mm. 
which binds to the AF-1 domain of ERα in a yeast two-hybrid assay (Merot et al., 2004), was 
tested under E2 conditions. In the absence of ER, the SRC-1 truncation mutants were not 
recruited to the array structure (data not shown). When this SRC-11051-1240 mutant was co-
transfected with ERα, the SRC-1 mutant was specifically recruited to the array structure by 
ERα, preventing recruitment of RNA polymerase II to the now condensed array structure, which 
is indicative of an inactive promoter region (Fig. 2E). The SRC-11051-1240 mutant was not 
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recruited to the array by ERβ and therefore could not prevent RNA polymerase II accumulation 
on the array structure. Swapping the AF-1 domains of ERα and ERβ resulted in exchange of 
the effect of the SRC-1 truncation mutant to interfere with accumulation of RNA polymerase 
II. The results of these inhibition studies indicated that the AF-1 domain of ERα is capable of 
binding to the Q-rich region of SRC-1, unlike the AF-1 domain of ERβ. These data were verified 
in a co-immunoprecipitation experiment (supplementary material Fig. S3). Blocking AF-2 
using a second SRC-1 truncation mutant (amino acids 623-711), which specifically binds to the 
AF-2 region of ER (Llopis et al., 2000), prevented RNA polymerase II recruitment for all tested 
ER constructs (supplementary material Fig. S4), resulting in a condensed array.
 The results of these binding studies indicate that the AF-2 domains of both ERα and 
ERβ directly interact with SRC-1, whereas only AF-1 of ERα is capable of interacting with the 
AF-1-binding domain of SRC-1.
 We next investigated the functional consequences of the difference in SRC-1 binding 
between the AF-1 domains of ERα and ERβ. We therefore performed an ERE-luciferase 
reporter assay, in which the function of AF-1, AF-2 or both in each of the ER constructs was 
inhibited by the different SRC-1 truncation mutants (see Fig. 3). A total of 10 nM E2 was added 
for all conditions, which resulted in maximal transactivation for each construct (Fig. 1B). The 
extent of transactivation of ERα was much higher than that of ERβ. The response of ERα 
was significantly reduced by co-transfection of SRC-1 truncation mutants that inhibit either 
AF-1 or AF-2. This was not the case for ERβ, for which only transcriptional inhibition by the 
AF-2-binding, but not by the AF- 1-binding, SRC-1 truncation mutant occurred. Exchanging 
AF-1 of ERβ for that of ERα in ERβAF-1α rendered this construct dependent on AF-1 for its 
transcriptional potency.
 These results indicate that the extent of transactivation by E2 is largely determined 
by both the AF-1 and AF-2 domains of ERα. Because the AF-1 domain of ERβ lacks the ability to 
bind to SRC-1, this synergism is absent in ERβ. The E2-mediated transactivation of ERβ, which 
is low in comparison to that of ERα, is due to the transactivation capacity of its AF-2 domain. 
Replacement of AF-1 of ERβ by the AF-1 domain of ERα in ERβAF-1α restored the synergism 
between both domains, although not to the extent observed with ERα.
Fig. 3. Functional synergy between 
AF-1 and AF-2 is ER and AF-1 
specific. An ERE-luciferase reporter 
assay was performed in U2OS cells 
transfected with the ER variants, the 
ERE-luciferase reporter construct and 
Renilla luciferase as a control. Where 
indicated, cells were co-transfected 
with SRC-1 amino acids 1051-1240 or 
SRC-1 amino acids 623-711, inhibiting 
AF-1 or AF-2, respectively (AF-1 and 
AF-2 block). Cells were treated with 
10 nM E2 or 100 nM tamoxifen or 
left untreated (CTS) for 36 hours, 
after which cells were lysed and the 
luciferase activity was determined. 
Representative data from two independent experiments is shown. Error bars indicate standard 
deviation from duplicate samples. The asterisk indicates a statistically significant reduction of 
luciferase signal by the AF-1 block, P<0.05.
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Effect of the hinge region on E2-driven transactivation by ER
 To investigate the differences in the extent of transactivation by E2 between wild-
type ERα and ERβAF-1α, we exchanged the hinge region of ERα for that of ERβ and vice versa 
(Fig. 4A), and tested these constructs in an ERE-dependent luciferase reporter assay using 
various concentrations of E2 (see Fig. 4B). A detailed alignment of the hinge regions of ERα 
and ERβ, as well as the hinge mutants, is shown in supplementary material Fig. S5. Two differ-
ent hinge swaps were made for each ER subtype: a small swap in which amino acids 294-309 in 
ERα were replaced with corresponding amino acids 253-262 in ERβ and a larger swap in which 
amino acids 256-332 in ERα were replaced with corresponding amino acids 225-283 in ERβ. 
Upon transfection of these constructs, similar mRNA levels were detected for all of the mu-
tants applied (supplementary material Fig. S2). The small hinge swap, ERαShingeβ, showed a
similar response to E2 as wild-type ERα, whereas the large hinge swap, ERαLhingeβ, resulted 
in decreased transactivation, similar to that of ERβAF-1α (Fig. 4B). This suggests that the re-
duced response of the ERβAF-1α mutant, in which the AF-1 region has been replaced with 
that of ERα, is due to the composition and/or length of the hinge region. No effect on maximal 
transactivation of the hingeswap mutants of ERβ was observed; both mutants behaved simi-
larly to wild-type ERβ or ERαAF-1β. This might be because of the absence of any AF-1 activity 
in ERβ, preventing hinge-mediated functional synergy between AF-1 and AF-2.
Fig. 4. The hinge region enables complete AF1 
and AF2 synergy in ER . (A) Structural overview 
of ERα, ERβ and its hinge-swap mutants used in 
this experiment. (B) The ERE-luciferase reporter 
assay was performed in U2OS cells transfected 
with ER variants, the EREluciferase reporter 
construct and Renilla luciferase as the control. 
Cells were treated with 10–12, 10–11, 10–10, 10–9,
10–8 M E2 for 36 hours or left untreated (CTS), and relative luciferase activity was measured. A repre-
sentative experiment out of three independent tests is shown. Error bars indicate standard deviation 




 Synergy between AF-1 and AF-2 is also essential for the agonistic behavior of tamoxifen 
(Zwart et al., 2007a). We therefore studied the role of the hinge region in the synergy involved in 
tamoxifen response. The tamoxifen response of the ERα large hingeswap mutant was impaired, 
whereas that of the ERα small hingeswap mutant resembled ERα (Fig. 4C). Tamoxifen did not 
increase the response of any of the ERβ hinge-swap mutants. Interestingly, exchanging the hinge 
region of ERα for that of ERβ in the ERα large hinge-swap mutant, resulted in a tenfold shift in EC50 
(effector concentration for half-maximum response) values in the response curves for E2 (Fig. 4B), as 
well as for tamoxifen (Fig. 4C), indicating that the ligand efficacy is influenced by the hinge region. 
The EC50 of the ERβ hinge mutants was also affected (Fig. 4B). This does not involve AF-1 and AF-2 
functional synergy, but is determined by the hinge region alone.
 Taken together, these results indicate that full E2-driven transactivation of ERα 
involves cooperation of the AF-1 and AF-2 domains that is dependent on the length and/or 
composition of the hinge region. For ERβ, E2-mediated transactivation is associated with only 
its AF-2 domain.
The hinge domain determines tamoxifen- and PKA-induced conformational alterations in ERα and ERβ
 After tamoxifen binding to ERα, a conformational change is induced in the receptor, 
which is indicative of ERα inactivation (Michalides et al., 2004; Zwart et al., 2007b; Zwart et 
al., 2009). This conformational alteration can be monitored by intramolecular fluorescence 
resonance energy transfer (FRET), in which two fluorophores (typically CFP and YFP) are 
fused to both termini of the receptor. FRET is the radiationless energy transfer from a donor 
fluorophore to a suitable acceptor fluorophore, and is highly dependent on the distance 
between them and their orientation (Förster, 1948), enabling a probe to monitor even 
subtle conformational changes. In the case of tamoxifen resistance, as induced by protein 
kinase A (PKA)-mediated phosphorylation of serine 305 close to the hinge region of ERα, 
this tamoxifen-induced conformational change does not occur (Michalides et al., 2004). To 
monitor the possible influence of the hinge region on the conformational changes induced by 
ligand binding, we tested the effect of tamoxifen and PKA activation on the FRET responses of
the swap mutants (Fig. 5). We monitored FRET by fluorescent lifetime imaging microscopy 
(FLIM), in which the lifetime of the donor fluorophore emission is measured. The lifetime 
of the donor CFP is typically 2.7 ns (Vermeer et al., 2004) and is reduced when the energy 
of the donor is transferred to the acceptor fluorophore in the case of FRET (Bastiaens and 
Squire, 1999). Cells expressing YFP-ER-CFP were co-cultured with cells only expressing CFP 
to provide an internal control for the FLIM measurements (Zwart et al., 2009). As we reported 
previously for ERα, the FRET signal was increased by treating the cells with tamoxifen, which 
could be prevented by pre-incubation with the PKA activator forskolin (Michalides et al., 
2004). In the case of ERβ, no increase in FRET signal was detected after tamoxifen treatment 
and after forskolin treatment. Combining both treatments, however, did induce a significant 
increase in FRET efficiency. When the hinge regions of both receptors were swapped, the 
characteristic responses to tamoxifen and PKA activation were also exchanged between 
receptors; ERαLhingeβ did not show a large increase in FRET efficiency after tamoxifen or 
forskolin exposure, whereas combination of these treatments did induce a conformational 
change. These FRET characteristics of ERαLhingeβ are therefore comparable to those of 
ERβ. ERβLhingeα showed a response comparable to ERα and tamoxifen now induced a FRET 
change. The combination of tamoxifen and forskolin treatment did not induce an increase in 
FRET for the ERβLhingeα mutant, whereas this was observed for wild-type ERβ. Therefore, 
introducing the hinge of ERα into ERβ sufficed to swap the ligand-induced conformational 
characteristics. The small hinge swaps showed intermediate effects. There were no differences 
in transcriptional potency, as induced by tamoxifen and forskolin, between the ER hinge-
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swap mutants (supplementary material Fig. S6). This indicated that the N- and C-terminal 
orientations within the ER variants are determined by the non-conserved hinge regions in ERα
and ERβ. More importantly, this hinge-specific feature appeared to be responsible for the 
different conformational responses induced by ligand treatment and kinase activities. 
Fig. 5. Tamoxifen and PKA-
induced conformational 
changes of ER and hinge 
mutants. Intramolecular 
FRET, as determined by 
FLIM, was measured in 
U2OS cells expressing YFP-
ERα-CFP, YFP-ERβ-CFP or 
their hinge-swap mutants. 
FRET was determined prior 
to ligand addition, after 1 
mM tamoxifen addition or 
PKA activation by 10 mM 
forskolin, or a combination 
of both treatments in CTS. 
Donor FRET efficiency (ED) 
was calculated as ED=1–
(lifetime cell of interest/
lifetime reference cell). For 
each condition, n>25 cells.
Discussion
 ERβ arose from ERα by a duplication event to different chromosomes approximately 
450 million years ago (Kelley and Thackray, 1999). The homology between the receptors is 
largely maintained in the DNA-binding domains (96%) and ligand-binding domains (53%), 
which indicates a functional selection pressure. In the present study, we confirmed previous 
work (Metivier et al., 2001) showing that the AF-1 domain of ERα binds to SRC-1. This binding, 
in combination with the hinge region of ERα, is responsible for the extent of transactivation 
by E2 and for ligand-independent transactivation. Both of these functions are lost in ERβ, 
which reflects the largely deviating sequence of AF-1 and the hinge region of ERβ compared 
with ERα. The expression of ERα and ERβ is different in various human tissues, ranging from 
exclusive expression of ERβ in the colon and brain to variations in the relative expression of 
ERα and ERβ in other tissues. This variation influences the extent of response to E2. Indeed, 
ERβ has been reported to interfere with E2-driven proliferation of breast cancer cells (Strom 
et al., 2004), either as homodimers or as heterodimers of ERα and ERβ (Li et al., 2004).
 Our study confirms a previous report (McInerney et al., 1998) and illustrates that 
the AF-1 domain of ERα is crucial for enhanced transactivation by E2. This is mediated by a 
unique feature of AF-1 of ERα, because it directly interacts with the Q-rich region of the SRC-1 
cofactor (Metivier et al., 2001), whereas AF-1 of ERβ does not. As a consequence, the small E2-
driven transactivation and RNA polymerase II recruitment by ERβ is solely mediated through 
its AF-2 activity. We also showed that the orientation between the AF-1 and AF-2 domains, 




 The results of the luciferase reporter studies (Fig. 3) confirmed the co-immuno-
precipitation experiments (supplementary material Fig. S3) and in situ localization studies 
(Fig. 2). These results showed that non-liganded ERα binds to SRC-1 through its AF-1 domain, 
which is sufficient for RNA polymerase II recruitment. The composition of the AF-1 domain is 
crucial for binding to SRC-1, whereas the spacing and/or orientation between the AF-1 and 
AF-2 domains are essential for transactivation of ERα. When the large hinge region of ERα was 
replaced with that of ERβ, the resulting ERαLhingeβ mutant was equally active as the ERβAF-
1α mutant (Fig. 4). This suggests that a combination of AF-1–AF-2 interactions, together with 
the hinge region, determines the prominent E2-driven transactivation of ERα. This spatial 
positioning of the AF domains might also be relevant for resistance to particular antagonists, 
because phosphorylation of serine 305 of ERα within the hinge region by protein kinase A or 
PAK-1 (Michalides et al., 2004; Rayala et al., 2006) results in resistance to tamoxifen.
 Both the length and the composition of the hinge region might affect the capacity 
for transactivation, because the hinge region of ERα is a target of extensive post-translational 
modifications that affect the stability and/or activity of the receptor. In particular, the residues 
in the hinge between K299 and S305 are targeted for acetylation, ubiquitylation, methylation 
and phosphorylation. These modifications might interfere with one another and affect final 
activation of ERα (Eakin et al., 2007; Kim et al., 2006; Michalides et al., 2004; Subramanian et al., 
2008; Wang et al., 2001). These sequences and corresponding opportunities for modification 
and modulation of the receptor are lacking in the hinge region of ERβ. Indeed, exchanging the 
hinge regions between ERα and ERβ altered the conformation of ER, as induced by tamoxifen 
and the PKA-activating compound forskolin (Fig. 5).
 The antagonist tamoxifen also has weak agonistic activity (32). We showed that the 
AF-1 domain of ERα enhanced this tamoxifenmediated transactivation, but only on an ERα 
background (Fig. 1C). This background involves the proper hinge region, which facilitates 
interaction between AF-1 and AF-2 and thereby the extent of transactivation for ERα, but not 
for ERβ (Fig. 4C).
 We have performed these studies in U2OS osteosarcoma cells; this is a model cell line 
for testing the direct effects of transactivation of ERα and ERβ (Michalides et al., 2004; Stossi 
et al., 2004), because these cells do not express endogenous ER and allow reconstitution of the 
ER-cofactor complex. We have focused in this study on the interaction between ER and SRC-1 
as a most relevant cofactor of ER. There are three different SRC cofactors, which all belong 
to the p160 cofactor family (Xu and Li, 2003). They interact with the AF-2 domain of ERα and 
ERβ through their LxxLL motifs (Heery et al., 1997). However, when AF-1 of ERα was blocked 
using an AF-1-inhibiting fragment of SRC-1 (Fig. 2), no recruitment of RNA polymerase II is 
observed in the presence of E2. These data showed that this SRC-1 truncation functions in a 
dominantnegative manner, implying no residual interaction between AF-1 of ERα and SRC-2 
or SRC-3 that would otherwise have resulted in recruitment of RNA polymerase II.
 It has been reported that AF-1 of ERβ binds to SRC-1 when the complex is bound to 
the SP-1-directed promoter of the TIEG gene in osteoblast cells, enhancing its E2-mediated 
expression (Hawse et al., 2008). This study and our results indicate that the effects of ERα 
and ERβ are dependent on the promoter region to which they (in)directly bind, as was also 
suggested by others (Klinge et al., 2004). The results of our study emphasize that, with the 
‘classical’ palindromic ERE-containing promoters, E2- and ligandindependent transactivation 
are determined by the binding of AF-1 of ERα and SRC-1, which does not occur in ERβ. 
AF-1 of human ERβ does not bind to SRC-1, unlike mouse ERβ (Tremblay et al., 1999). This 
corresponds to a difference in transactivation by E2 between human ERa and ERβ, whereas 
there is no such difference between mouse ERa and ERβ (Picard et al., 2008). In the mouse, 
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specific phosphorylation sites in the AF-1 domain of mouse ERβ can alter its activity (Tremblay 
et al., 1999) and stability (Picard et al., 2008).
 This difference between human ERα and ERβ also emphasizes the importance of 
domain interactions in ERα. The orientation between the AF-1 and AF-2 domains in ERα is 
affected by selective anti-estrogens and can be subtly modified by the structure of these anti-
estrogens. How the various domains of ERα and cofactors collaborate in breast-tumor growth 
and in the response to antiestrogens is gradually becoming clear.
Materials and Methods
Cell culture and antibodies
 Human osteosarcoma U2OS, MCF-7 and HeLa PRL array cells (Sharp et al., 2006) 
were cultured in DMEM medium in the presence of 10% FCS and standard antibiotics. Cells 
containing ER constructs were cultured in phenol-red-free DMEM containing 5% charcoal-
treated serum (CTS; HyClone). Antibodies used were raised against ERα (NovoCastra/Cell 
Signaling Technology), tubulin (Sigma), ERβ (Santa Cruz Biotechnology), RNA polymerase II 
(8WG16; Covance) and GFP (van Ham et al., 1997).
Cloning procedures and oligomers
 ERα, ERβ, SRC-1 (amino acids 623-711)-YFP and SRC-1 (amino acids 1051-1240)-
YFP constructs were generated as described previously (Michalides et al., 2004; Zwart 
et al., 2007a). The ERαAF-1β and ERβAF-1α swap constructs were made by pairwise 
ligation of four separate PCR fragments in a second PCR reaction. The AF-1a (amino acids 
1-180) and AF-1β (amino acids 1-144) fragments were made using forward primer (A) 
5’AATTGGATCCACCACCATGGCATACCCATACGACGTCCCAGACTACGCTATGACCATGACCCT
CCACACC and reverse primer (B) 5’GCGCAGAAGTGAGCATCCTTGGCAGATTCCATAGCC, and 
forward primer (C) 5’AATTGGAT CCACCACCATGGCATACCCATACGACGTCCCAGACTACGCTAT
GGATATAA AAAACTCACC and reverse primer (D) 5’GCACAGTAGCGAGTCTCCCTCTTTGAAC
CTGGACC, respectively, introducing a BamHI restriction site and a hemagglutinin 
tag at the 5’ ends, and a ERβ or ERα overhang at the 3’ends of the fragments. The 
ERαDAF-1 and ERβDAF-1 fragments, lacking the AF-1 regions, were made using forward 
primer (E) 5’GGTCCAGGTTCAAAGAGGGAGACTCGCTACTG TGC and reverse primer 
(F) 5’TGGGGGATCCTTATCAGACTGTG GCAG GGAAACC, and forward primer (G) 
5’GGCTATGGAATCTGCCAAGGATGCTCACTTCTGCGC and reverse primer (H) 
5’AATTGGATCCTCACTGAGA CTGTGGGTTCTGG, respectively, introducing a ERβ or ERα 
overhang at the 5’ ends, and a stop codon and BamHI restriction site at the 3’ ends of the 
fragments. The AF-1α and ERβDAF-1 and AF-1β and ERαDAF-1 fragments were then ligated to each 
other in a second PCR reaction using forward primer (A) and reverse primer (H), and forward 
primer (C) and reverse primer (F). These swap constructs were cloned in the dephosphorylated 
BamHI site of the pcDNA3 vector.
 ERαShingeb, ERαLhingeβ, ERβShingeα and ERβLhingeα constructs were made by
sequential PCR reactions, ligating ten separate smaller PCR fragments into four 
different larger fragments containing the chimeric hinge regions. The two PCR 
fragments used for the construction of ERαShingeβ (a.a. 253-262) were made using 
forward primer (1) 5’AATTCCGCGGCCGCCGCCAACGCGCAGG and reverse primer (2) 
5’GGCGTCCAGCAGCAGCTCCCGCACTCGGGGTGGCCAAAGGTTGGC, and forward primer 
(3) 5’CCCCGA GTGCGGGAGCTG CTGCTGGACGCCCTGACGGCCGACCAG and reverse 
primer (4) 5TGGTCTAGAAGGTGGACCTGATCATGGAG. The fragments were then ligated in 
a second PCR reaction using forward primer (1) and reverse primer (4), introducing a SacII 
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restriction site at the 5’ end and an XbaI site at the 3 end. This construct was then inserted 
into the corresponding restriction sites in a pcDNA3-ERα vector. The two PCR fragments 
used for the construction of ERβShingeα (a.a. 294-309) were made using forward primer 
(5) 5’CCAGATATCACTATGGAGTCTGGTCGTGTG and reverse primer (6) 5GGACAAGGCC 
AGGCTGTTCTTCTTAGAGCGTTTGATCATGAGCGGGCTCGCGTGGCCGCCACTTCTCTTGGCC, 
and forward primer (7) 5’AGCCCGCTCAT GATCA AACGCTCTAAGAAGAACAGCCTG GCCTTGT
CCCTGAGCCCCGAGCAGCTAGTGCTCACC and reverse primer (8) 5’TGGGAATTCCTTC TACG 
CATTTCCCCTCATCC. The fragments were then ligated in a second PCR reaction using forward 
primer (5) and reverse primer (8), and introducing an EcoRV restriction site at the 5 end and 
an EcoRI site at the 3’ end. This construct was then inserted into the corresponding restriction 
sites in a pcDNA3-ERβ vector.
 The three PCR fragments used for the construction of ERαLhingeβ 
(a.a. 220-283) were made using forward primer (1) and reverse primer (9) 
5’CACATCTCTCTCTCCGTATCCCACCTTTCATCATTCCC, forward primer (10) 
5’CGGAGAGAGAGATGTGGGTACC and reverse primer (11) 5’GCGGCTGA TCAGCACATGGGGC,
and forward primer (12) 5’TGTGCTGATCAGCCGCCCTACCAGACCCTTCAGTGAAGCTTCG and 
reverse primer (4). The fragments were then sequentially ligated in a second and third PCR 
reaction using forward primer (1) and reverse primer (11), and forward primer (1) and reverse 
primer (4), respectively, introducing a SacII restriction site at the 5 end and an XbaI site at the 
3’ end. This construct was then inserted into the corresponding restriction sites in a pcDNA3-
ERα vector.
 The three PCR fragments used for the construction of ERβLhingeα 
(a.a. 256-332) were made using forward primer (5) and reverse primer (13) 
5’CTCCTCTTCGGTCTTTTCGGGAGCCACACTTCACCATTCCC, forward primer (14) 5’CGAAAA
GACCGAAGAGGAGGGAG and reverse primer (15) 5’ATCATACTCGGAA TAGAGTATGGG, and 
forward primer (16) 5’CTCTATTCCGAGTATGATCCCAGTGCGCCCTTCACCGAGG and reverse 
primer (8). The fragments were then ligated in a sequential second and third PCR reaction 
using forward primer (5) and reverse primer (15), and forward primer (5) and reverse primer 
(8), respectively, introducing an EcoRV restriction site at the 5 end and an EcoRI site at the 3 
end. This construct was then inserted into the corresponding restriction sites in a pcDNA3-ERβ 
vector.
 For QPCR analysis of ER expression levels, hybrid primers were applied based on the 
two DNA-binding domains, with forward primer 5’GAGAAGCA TTCAAGGACATAACGAT and 
reverse primer 5’CCACATTTCACCATTCCCAC. As a control for equal loading, the observed ER 
signals were related to β-actin RNA levels, using a forward primer 5’CCTGGCACCCAGCACAAT 
and reverse primer 5’GGGCCGGACTCGTCATACT.
Immunoprecipitation
 U2OS cells were transfected with ERα, ERβ or ERβAF-1α in the presence or absence
of SRC-1 (amino acids 1051-1240)-YFP using polyethylenimine (PEI). Twenty-four hours after 
transfection, cells were lysed in 125 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Nonidet P-40, 
10 mM MgCl2 and protease inhibitor cocktail (Roche) on ice, sonificated and debris removed 
by centrifugation. The supernatant was used in immunoprecipitation using anti-GFP antibody 
immobilized on protein A-sepharose beads (Invitrogen) during incubation overnight. Samples 
were taken from the supernatant for analysis of the total lysate. Beads were extensively 
washed, boiled and samples were analyzed by western blotting. For detection, antibodies 
identifying ERα, ERβ and GFP were used, and the signal was detected using an ECL detection
kit (Amersham).
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ERE- and AP-1-dependent luciferase assays
 Luciferase assays were performed as described previously (Bindels et al., 2002), 
transfecting 2 ng of ER and 0.2 mg ERE-tk-firefly luciferase, or 0.2 mg of ER and 0.2 mg AP-1-tk-
firefly luciferase using PEI (25 kDa; Polysciences) (Boussif et al., 1995). As a control, 2 ng Simian 
virus (SV40) Renilla luciferase was used. For specific inhibition of the AF-1 or AF-2 activity of 
ERα, SRC-1 truncation mutants comprising amino acids 1051-1240-YFP or amino acids 623-
711-YFP (Zwart et al., 2007a) were co-transfected at 0.5 and 0.2 mg per well, respectively, and 
supplemented with pcDNA3 empty vector to equalize the total amount of DNA per well.
Microscopy
 RNA polymerase II recruitment was assayed as described before (Zwart et al., 2007a). 
Where indicated, cells were co-transfected with YFP-tagged SRC-1 fragments comprising 
amino acids 623-711 or amino acids 1051-1240. Two hours before fixation, cells were treated 
with 1 mM estradiol, tamoxifen or left untreated. Cells were fixed with 3.7% formaldehyde 
in PBS, permeabilized for 5 minutes with 0.05% Triton X-100 in PBS at room temperature, 
and subsequently stained with antibodies detecting ERα, ERβ and RNA polymerase II, and 
secondary antibodies conjugated to AlexaFluor405 and AlexaFluor647 (Molecular Probes). 
After staining, cells were mounted in Vectashield mounting medium (Vector Laboratories). 
The specimens were analyzed with confocal laser-scanning microscopes (TCS-SP1, TCS-SP2 
or AOBS; Leica) equipped with HCX Plan-Apochromat 63 NA 1.32 and HCX Plan-Apochromat 
lbd.bl 63NA 1.4 oil-corrected objective lenses (Leica). The acquisition software used was LCS 
(Leica).
Fluorescence lifetime imaging microscopy
 Prior to FLIM experiments, cells on cover slips were mounted in bicarbonate-buffered
saline (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 23 mM NaHCO3, 10 mM glucose 
and 10 mM HEPES at pH 7.3) in a heated tissue-culture chamber at 37°C under 5% CO2. 
FLIM experiments were performed on a Leica inverted DMIRE2 microscope equipped with a 
Lambert Instruments frequency domain lifetime attachment (Leutingewolde), controlled by 
the vendor’s LI FLIM software. CFP was excited at 430 nm with ~4 mW power using an LED 
modulated at 40 MHz. Emission was collected at 450-490 nm using an intensified CCD camera. 
FLIM measurements were performed in U2OS cells, transfected with YFP-ERα-CFP, YFP-ERβ-
CFP or one of the hinge-swap mutants. Calculated CFP lifetimes were referenced to a 1 mM 
solution of rhodamine-G6 in medium that was set at a 4.11 ns lifetime, and internally calibrated 
using co-cultured CFP containing MelJuSo reference cells, for which the lifetime was set to 2.7 
ns (Vermeer et al., 2004). Donor FRET efficiency (ED) was calculated as ED=1–(lifetime cell of 
interest/lifetime reference cell). 
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Supplementary material
Fig. S1. Sequence alignment of the N termini of ERα and ERβ. Highlighted in ERα are the AF-1 
transactivation regions (A box 1, A box 2, A box 3) and the small α-helical stretch (in red) that 
is essential, but not sufficient, for AF1 activity. Essential amino acids in this α-helical sequence 
are underlined.
Fig. S2. Activity and mRNA and protein levels of ER variants used in this study. (A) U2OS cells 
were transfected with ERα, ERβ or one of the swap mutants, RNA was isolated and mRNA 
levels of each ER variant were determined by quantitative RT-PCR. mRNA levels were related 
to the ERα level, which was set at 1. Data are from two independent experiments. Error bars 
show standard deviations. (B) Luciferase activity was measured in U2OS cells transfected with 
2 ng or 10 ng of ERα, ERβ or one of the AF-1 swap mutants. Cells were co-transfected with 
an ERE-luciferase reporter construct and Renilla luciferase reporter to correct for transfection 
efficiency. Cells were treated for 2 days with tamoxifen (10−7), E2 (10−8) or left untreated 
(CTS). All data were normalized to the CTS value of 2 ng ERα, which was set at 1. Error bars 
show standard deviations from triplicate samples. (C,D) Protein levels of ERα, ERβ or one of 
the swap mutants in U2OS cells were determined by western blot, with antibodies raised 
against ERα or ERβ (C). For expression testing of the FRET constructs, an antibody detecting 
GFP was used (D). Actin signal was used as a loading control.
Fig. S3. The AF-1 domain of ERα but not of ERβ binds to SRC-1. U2OS cells were transfected 
with ERα, ERβ or one of the AF-1 swap mutants, and co-transfected with SRC-11051-
1240-YFP where indicated. SCR-11051-1240 was immunoprecipitated, after which the co-
immunoprecipitated ER was identified using antibodies against ERα and ERβ. The arrow 
indicates the SRC-11051-1240-YFP signal, detected below the IgG background band.
Fig. S4. AF-2-dependent SRC-1 recruitment to the PRL array structures. PRL arrays containing 
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HeLa cells were transfected with one of the different ER constructs and with the SRC-1623-
711-YFP (AF-2 inhibiting) truncation mutant, and subsequently treated with 10−6 M E2. 
Arrowheads indicate the array structure, analyzed for the presence of the SRC-1-YFP fragment 
and RNA polymerase II (close up shown in inset). Scale bar: 5 µm.
Fig. S5. Sequence alignment of the hinge regions of ERα, ERβ and the corresponding hinge 
swaps. Highlighted in red are the NLS consensus sequences in both ER variants. The described 
targets of PKA in ERα (S236 and S305) and ERβ (S200) are also indicated.
Fig. S6. PKA activity enhances the tamoxifen response for ERα hinge swaps. Luciferase activity 
was measured in U2OS cells transfected with ERα, ERβ or one of the hinge-swap mutants. 
Cells were co-transfected with an ERE-luciferase reporter construct and Renilla luciferase 
reporter to correct for transfection efficiency. Cells were treated for 2 days with tamoxifen 
(10−7 M) or left untreated. The last 16 hours, cells were co-treated with 100 µM 8-Br-cAMP to 
activate PKA. All data were normalized to the CTS value of ERα, which was set at 1. Error bars 
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A high-throughput coregulator peptide array detects estrogen 
receptor alpha Serine-305 phosphorylation to predict responses to 
tamoxifen
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Martens, Jacques Neefjes,  Rob Michalides 
Abstract
 With current techniques it remains a challenge to assess coregulator binding of 
nuclear receptors, e.g. the estrogen receptor alpha (ERα). ERα is critical in many breast tumors 
and is inhibited by antiestrogens such as tamoxifen in cancer therapy. ERα is also modified 
by acetylation and phosphorylation that affect responses to the anti-estrogens as well as 
interactions with co-regulators. Phosphorylation of ERα at Ser305 is one of the mechanisms 
causing tamoxifen resistance. Detection of resistance in patient samples would greatly 
facilitate clinical decisions on treatment, where such patients would receive other treatments 
such as aromatase inhibitors or fulvestrant.  Here we describe a coregulator peptide array that 
can be used for high throughput analysis of full-length estrogen receptor binding. The peptide 
chip can detect ERα binding in cell and tumor lysates. We show that ERα phosphorylated 
at Ser305 associates stronger to various coregulator peptides on the chip. This implies that 
ERαSer305 phosphorylation increases estrogen receptor function. As this is also detected in 
a breast tumor sample of a tamoxifen insensitive patient, the peptide array as described here 
may be applicable to detect tamoxifen resistance in breast tumor samples at an early stage of 
disease and contribute to personalized medicine.
Introduction
 Nuclear receptors (NRs) regulate gene expression levels by gene promotor binding 
and by recruitment of coregulators (1). Modulation of NR activity is usually quantitatively 
analyzed by assaying target gene transcription or downstream events. These parameters 
are however the net result of the NR interaction with a wide range of individual coregulators. 
Thus far, studying nuclear receptor interactions with coregulators in a more global manner 
has been a challenge. Conventional methods providing NR-coregulator interaction data 
are intermolecular FRET, Y2H, phage display and colocalization studies in fluorescence 
microscopy (2-4). These techniques generally allow the study of one receptor-coregulator pair 
while nuclear receptors usually have multiple coregulators to choose from and the biological 
outcome of activation of the receptors then depends on the different coregulators expressed 
and their relative affinity to the nuclear receptor. Here we apply a peptide array that can assess 
interaction of full length estrogen receptor alpha (ERα) with a set of coregulators, in a high 
throughput manner. Apart from the ligand, post-translational modifications (PTM) also play 
a major role in NR transactivation and can yield differential response to ligands (5-13). It is 
therefore likely that PTMs can also play a role in coregulator recruitment.
 The most widely studied group of estrogen receptor alpha (ERα) coregulators 
includes the p160 protein family, consisting of three members: NCOA1 (SRC-1), NCOA2 (SRC-
2) and NCOA3 (SRC-3) (14-16), which have specific effects (14). Moreover, NCOA3 (AIB1) 
gene amplification and elevated expression was discovered in a subset of ERα-positive breast 
cancer (17, 18). Endocrine therapy, which aims for inactivation of ERα, uses competitive 
estrogen antagonists (e.g. tamoxifen) or aromatase inhibitors that block estrogen synthesis. 
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This prevents the formation of the coactivator binding surface on ERα (19). A group of 
patients does not respond to endocrine therapy, because ERα remains transcriptionally active 
despite endocrine treatment. One factor that is associated with resistance to tamoxifen is 
phosphorylation of ERα Serine 305 (ERαS305-P) by protein kinase A (PKA) (11, 20, 21). This 
post-translational modification affects receptor function by a conformational change that 
alters binding to NCOA-1 (22). Since ERα transcriptional activity is defined by interaction of the 
receptor with a multitude of different coregulators, we set out to develop a high throughput 
assay to functionally analyze the interaction of ERα and its Ser305-P modified form with a 
broader panel of coregulators. In this study, we applied an array on which a set of peptides 
representing coregulator NR-box sequences are immobilized (23). This format allows for high 
throughput in vitro functional analysis of ERα, i.e. coregulator interaction, and modulation 
by ligand and receptor phosphorylation. We do detect differences in binding upon one single 
post-translational modification: phosphorylation of ERα Serine 305 and show that our assay 
allows detection of phosphorylation-correlated alteration of ERα activity in breast tumor 
lysates as a first step towards developing a test to detect resistance to anti-estrogens such as 
tamoxifen.
Materials and Methods
DNA constructs, cell culturing and transfections
 pcDNA3-YFP-ERα-CFP transfected human U2OS osteosarcoma cells and human 
MCF-7 breast cancer cells were cultured in DMEM medium in the presence of 10% FCS and 
standard antibiotics. Cells were transferred to phenol red-free DMEM containing 5% charcoal 
treated serum (CTS, Hyclone) prior to the addition of ligands (for MCF7 cells) in order to omit 
the estrogenic effect of phenol red and serum-estrogens as described previously (11). 
Sample preparation
 ERα transfected U2OS cells or MCF7 cells, 48 hours after transfection, were 
harvested in 1 ml TNRL01-lysisbuffer (24) using a cell scraper. Cells were subsequently lysed by 
sonification using a Branson sonifier for 10 pulses at output 50% and duty cycle 5. Lysates were 
aliquoted and flash frozen in liquid nitrogen. ERα in the samples was quantified using ELISA 
(Acive Motif). Equal amounts of ERα wild-type (ERα WT) were used in further experiments. 
Deep-frozen breast tumor samples were immediately pulverized using a dismembrator and 
processed in TNRL01-lysisbuffer as described previously (24). Equal amounts of protein were 
separated by SDS-PAGE, blotted and the filter was probed with antibodies against GFP (25), 
ERαSer305-P (Millipore, #124.9.4.9, (21)) and ERα (HC20, Santa Cruz). Human actin (I19, 
Santa Cruz) was used as the loading control. Signals were detected using an ECL detection kit 
(Amersham). Experiments were repeated at least twice, with reproducible results. 
Phosphatase treatment of tumor lysates
 Per array, 5 ml tumor lysate was incubated for 45 minutes at 30°C in a reaction 
volume of 5ml of lambda protein phosphatase buffer, 5 mM DTT and 30U lambda protein 
phosphatase (#14-405, Millipore). Treatments were ended by adding 5µl of the stopbuffer 
with HALT protease inhibitor cocktail (PIERCE) and phosphatase inhibitors (100mM NaF, 
80mM B-glycerophosphate and 2 mM orthovanadate). Subsequently, samples were directly 
supplemented with the MARCoNI assay mix and analysed (30).
Micro Array assay for Real-time analysis of Coregulator-Nuclear receptor Interaction
 All assays were performed in a PamStation®-96 (PS96) controlled by EvolveHT 
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software (PamGene International BV, Den Bosch, the Netherlands) (26, 27). Nuclear Receptor 
PamChip® Arrays (PamGene International BV, Den Bosch, the Netherlands) with immobilized 
peptides with coregulator derived sequences (Suppl. table 1).  Lysate assay mixes contained 
10 µl lysate, 4 µg/ml Alexa488-conjugated anti-GFP antibody (#A21311, Invitrogen, Carlsbad, 
USA) in Tris-buffered Saline (TBS) containing 0.05% Tween 20, 0.2% BSA, 50 µM DTT, 2% DMSO 
(with or without E2). The assay mix with ERα LBD-GST (#PV4543; Invitrogen, Carlsbad, USA) 
was prepared as described previously (22, 28) using 4 µg/ml Alexa488-conjugated anti-GST 
(#A11131, Invitrogen, Carlsbad, USA) as detecting antibody. Mixes were prepared and stored 
on ice in a master 96 well plate until use. All incubations were performed at 20°C, applying a 
sample rate of 2 cycles per minute. The initial blocking was performed by incubating the arrays 
for 20 cycles with 25 ml blocking buffer (TBS with 1% BSA, 0.01%, Tween-20 and 0.3% skimmed 
milk (Oxoid)). After removal of the blocking buffer by aspiration, each array was incubated 
with 25 ml of assay mix for 80 cycles, washed with 25 µl TBS and finally (cycle 102) a tiff format 
image was obtained by the CCD camera. Image analysis consisting of automated spot finding 
and quantification was performed using BioNavigator software (PamGene International 
BV, Den Bosch, the Netherlands). In short, the boundaries of a spot are determined and the 
median fluorescent signal was quantified within the spot (signal) as well as that in a defined 
area surrounding it (background). The signal-minus-background value was subsequently used 
as the quantitative parameter of binding.
 Ligand dose-responses were analyzed using the drc package in R (version 2.12.0, 
www.r-project.org). Sigmoidal dose-response curves (DRC) were fitted using a four-parameter 
logistic model and delivered values for potency (EC50) and for efficacy (signal difference 
between the bottom and top value of the curve).   
 Z-score normalization, or standard score, which converts the absolute value (binding) 
of a data point in a population (profile) into the distance of that data point to the mean of 
the population in units of the standard deviation of that population, was calculated as 
(bindingpeptide-mean(bindingall peptides))/stdev(bindingall peptides).
Results
Co-factor binding profile of full-length ERα 
 We generated a peptide array containing a series of peptides representing co-
regulator binding sites (set 1, Suppl. table 1). This series of peptides included most of the 
known cofactors interacting with ERα. To test whether ERα was able to bind to these peptides, 
we produced lysates from U2OS cells expressing fluorescently tagged ERα (ERαY/C, figure 
1C).  First, we analyzed the binding profile of ERα, treating the cells with different ligands prior 
to lysis (pre-lysis ligand treatment, pre-LT). The results showed a binding pattern for ERα to 
the coregulator motifs when stimulated with E2, whereas hardly any binding was observed for 
non-liganded or tamoxifen-bound ERα (figure 1D).
 Next, we investigated whether addition of ligands could still modulate the binding of 
ERα to coregulators after lysis (post-LT). Treating the samples before or after lysing the cells 
with E2 resulted in a similar binding profile (figure 1D/E). This indicates that the full-length 
receptor stays functional in terms of ligand binding and coregulator recruitment in crude 
lysates as well. This allowed us to consider one crude lysate in different treatment strategies 
followed by functional analysis of ERα on the array.
 
Full-length ERα versus ERα-LBD
 Isolating full-length nuclear receptors is time consuming and difficult (29, 30). In 
our experiments we used crude lysates, instead of purified proteins. Another, more common 
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Figure 1. Analysis of coregulator binding of full-length ERα in crude lysates of transfected 
cells. A. U2OS cells transfected with a YFP-ERα-CFP (ERα Y/C) construct.  Transfectants were 
I: treated with ligand or kept under hormone-free conditions and lysed (Pre-LT), or II: lysed 
first and ligand was added to the lysate (post-LT), finally ERα in the samples was subjected 
to functional analysis by MARCoNI. B. Schematic overview of peptide array technology.. C. 
Western blot analysis of ERαY/C expression in transfected U2OS cells detected with anti-
GFP. D.  Peptide  binding (in arbitrary units of fluorescent signal, detected with anti-GFP-
ALEXA488) of ERα Y/C in samples  obtained by  pre-LT or  E. post-LT  to a set of 25 immobilized 
coregulator-derived LxxLL motives, in response to 17-b-estradiol  (E2),  4-hydroxy-tamoxifen 
(4-OHT) or absence of ligand  (Veh). For peptides, see corresponding numbers in Suppl. table 1.
approach is using the ligand binding domain (ERα-LBD) (27, 31). We therefore compared 
the E2-response of the ERα-LBD with that of the full-length protein in lysates of ERαY/C 
transfectants. Both protein preparations were incubated at different concentrations of E2 
(ranging from 10-12 to 10-7M) 10 minutes before loading of the samples onto the array. Curves 
for all peptides were visually inspected. Full receptor saturation with ligand was achieved for 
both proteins, reflected by a binding plateau for all peptides at the high-end of the ligand 
concentration range. As an example, E2 binding curves of ERαY/C and ERα-LBD to a control 
peptide (NCOA1-677-700: IDNR 13 in Suppl. table 1) are shown in figure 2A.
 The E2 potency (EC50) for each peptide was derived from these curves. EC50 values 
for all peptides (Supplementary Table 1, set I) were in the low nM range for both ERα and ERα-
LBD (data not shown) and corresponded with published data (32). Ligand-independent binding 
(LIB) and ligand-saturated binding (LSB) were calculated for each peptide on the array from 
the signal at the two lowest and two highest E2 concentrations respectively, each performed 
in duplicate arrays. E2-induced modulation of ERα binding to each peptide is represented as 
the modulation index (MI), which is the log-10 transformed ratio of the LSB over LIB (figure 
2B/C).
 The MI values of purified ERα-LBD protein were similar to those of the cell lysates with 
full-length ERα (figure 2B). The coefficient of correlation (R2) between the E2- induced binding 
profiles of both proteins was 0.86 (figure 2B scatterplot). The overall E2-MI for full-length 
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ERα was slightly higher than for the ERα-LBD fragment, suggesting more efficient binding to 
coregulators. As shown previously, coregulator binding does not require, but is enhanced by 
the presence of the AF-1 domain (22, 32) The AF-1 domain is absent in the ERα-LBD construct 
which therefore binds less efficiently to cofactors. The specificity of the interactions is not 
affected.
Figure 2.  E2-induced modulation of ERα-coregulator binding: purified ligand-binding domain vs. full-
length protein in crude lysates. Recombinant ERαLBD-GST or ERαY/C lysate was incubated with a 
concentration range of E2 (10-12 to 10-7M), one chip per ligand concentration. Each condition was 
measured in duplicate (2 arrays) and receptor binding was visualized using ALEXA488-conjugated 
anti-GST or anti-GFP respectively. A. The E2 EC50 values were calculated from the resulting dose-
response curves. E2-induced modulation of the binding to each peptide was indicated by the 
modulation index (MI) which is the log-10 transformed ratio of LSB over LIB. Example of E2 dose-
response curves of the full-length ERαY/C (left) and ERα-LBD- (right) binding to a NCOA1-derived 
peptide (IDNR13). B. E2-induced MI of ERα-LBD and full-length receptor binding to the NR-boxes 
are shown. Subgraph: Scatter plot and correlation coefficient of E2- MI of ERαLBD-GST vs. full-
length ERαY/C. C. MI of MCF7 endogenous ERα and U2OS full-length ERαY/C, subgraph represents 
correlation. For peptides, see corresponding numbers in Suppl. table 1.
Exogenous versus endogenous ERα in cell lysates
 The results of the experiments described thus far indicated that the full-length ERα 
from transfected cells behaved similarly in this analysis as ERα-LBD fragments that were 
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generated in vitro.  This full length ERα construct contained two GFP variants for detection 
and this might affect binding efficacy. Therefore, we compared the tagged full-length ERα 
from transfected U2OS cells with an endogenous ERα from the human breast cancer cell line 
MCF7. The E2-induced binding of ERα in transfected U2OS and in MCF cells was highly similar 
(R2:0.72), although the absolute signal was slightly enhanced in the latter sample (Figure 2C). 
This suggests that the YFP and CPF tags do not affect receptor function and that the assay does 
not require overexpression of ERα and also is sensitive enough to be used for endogenous ERα 
protein in lysates.
ERα from ER-positive breast cancer
 Since we could detect binding of endogenous ERα in crude lysates to the chip, we 
decided to test the technology on breast tumor material.  We prepared lysates from a primary 
ERα-positive breast tumor sample. E2 (1 µM) or no ligand (control) was added 10 minutes prior 
to loading onto the array. The results showed that ERα from tumor material is still responsive 
to E2 (figure 3A) and the E2 response (MI) of ERα in these samples resembles that of MCF7 cells 
(R2:0.78, figure 3B).  
Figure 3. Coregulator binding of ERα from in breast tumors and binding modulation by estradiol. A. 
Coregulator binding of ERα in a tumor in the absence or presence of ligand (E2). B. E2-induced modulation 
indices (MI) of MCF7- and breast tumor-derived ERα, subgraph represents correlation. C. Extracts from 
three different ERα-positive breast tumors and MCF7 were incubated in the presence of E2 or vehicle. 
ERα binding was visualized with anti-ERα and FITC-labeled secondary antibody. Binding profiles were 
normalized using z-score transformation, (x-xmean)/sd(x) for direct comparison between the three tumors.
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 Clinical samples generally show heterogeneity. To investigate whether this plays a 
role in our peptide chip, we compared three ERα-positive breast tumors. Absolute differences 
in signal between the three tumor samples were observed. The signals were adjusted by z-score 
normalization, which enables a direct comparison of the profiles. Addition of E2 modulated 
the binding profiles of all tumors. Moreover, the endogenous (CTS) binding profiles as well 
as under saturating E2 concentration were highly similar between tumors (Figure 3C). These 
data indicate that the analysis of human tumors and cell lines by the cofactor peptide array is 
consistent and reproducible and thereby suitable for identifying cofactor binding to ERα from 
human breast cancer specimens under different ligand conditions.
Functional analysis of ERα Serine305 phosphorylation
 Post-translational modifications on ERα and other nuclear receptors have been shown 
to influence coregulator binding, but this has been demonstrated only on single coregulators 
(22). We investigated whether the effect of such modifications could be monitored in our high-
throughput assay. From this point we included more peptides from cofactors binding to ERα or 
to some other NRs, in addition to set I (Supplementary Table 1, set II). PKA-induced ERαS305-P 
has been linked to resistance to tamoxifen treatment (20, 21). Under tamoxifen conditions, 
this phosphorylation affects the conformation of ERα and changes its orientation to NCOA-1 
(22). Here we studied the effect of ERαS305-P on the binding of cofactors in transfected cells 
and in breast tumor specimens. We therefore applied a next generation array with an extended 
set of 52 coregulator peptides (set II, Suppl. table 1). The serine305-to-alanine mutant (ERαY/C 
305A) was included as a negative control (Figure 4A). Next, we generated lysates that were 
incubated with a concentration range of up to 10-8M E2 and analyzed binding to the co-factor 
peptides on the chip. This resulted in a dose-dependent modulation of ERα binding to each 
coregulator peptide on the array, as illustrated for the control peptide (IDNR13) in Figure 4B. 
Wild-type (WT) and mutant ERα (305A) from control and 8-Br-cAMP-stimulated cells were 
responsive to E2. From unstimulated cells, the ligand-independent binding (LIB, left extreme 
of the curves) of wild-type ERα is slightly enhanced when compared to 305A mutant receptor. 
This may be due to some background phosphorylation of wild-type ERα at this residue in 
unstimulated cells (figure 4A). When 8-Br-cAMP activates PKA, both LIB and E2-saturated 
binding (LSB) to this peptide were elevated. This was observed for both the wild-type receptor 
and 305A mutant, but the effect on wild-type ERα is more substantial (Figure 4C). This has 
been observed for all peptides on the array and suggests that ERαS305-P increases the ERα 
binding affinities in absence of ligand (figure 4D) and amplifies the E2-induced modulation of 
binding (figure 4E) to various coregulators.
 Of note, additional phosphorylation sites may play a role in the residual cAMP effect 
seen in the ERαY/C 305A (Figure 4D), which is not completely abolished by the mutation of this 
site. A plausible candidate is Serine 236 in ERα (33). Therefore, we assessed binding of the ERα 
double mutant (236A/305A), in which none of the two known PKA target sites could become 
phosphorylated, to the control peptide. The PKA-enhanced binding to ERα WT was partially 
reduced by the single Ser305Ala mutation, but almost completely abrogated in the double 
mutant (Fig 4C). This indicates that the PKA-associated effect on binding to this peptide is 
mainly due to phosphorylation of ERα sites Ser236 and 305. 
 The effect of PKA activation on peptide binding was also studied under tamoxifen 
(4-OHT) conditions. This is illustrated by ERα binding to the same peptide (IDNR13) using a 
concentration range of up to 10-5M 4-OH-tamoxifen (Figure 5A). Although PKA activation 
increased the initial binding (LIB) of ERα WT, binding of both ERα and ERαS305A were strongly 
diminished at saturating tamoxifen concentrations. The potency (EC50) of 4-OH-tamoxifen 
was not affected and largely similar for the various motifs on the chip (figure 5C). This implies 
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that enhanced ERα activity by phosphorylation could result in ligand independent activation 
and/or enhanced responses to E2, and may result in enhanced residual receptor activity at 
non-saturating tamoxifen levels.
Figure 4.  Effect of serine 305 phosphorylation on ERα-coregulator binding.  U2OS cells were 
transfected with wild-type (WT), single (305A) or double (236A-305A) serine mutant full-length 
ERα tagged with YFP/CFP.  Cells were stimulated with (+) or without cAMP to induce PKA-
mediated receptor phosphorylation.  A. Western blot analysis of ERαSer305 phosphorylation in 
the three transfectants with or without cAMP stimulation.  B. Dose dependent 17-β-Estradiol 
(E2)–modulated binding of wild-type or ERαY/C 305A from control or cAMP-stimulated cells 
with NCOA1_677_700 (IDNR13).  C.  cAMP-induced enhancement of NCOA1_677_700 binding by 
ERαY/C WT, ERαSer305Ala and ERαSer305Ala/Ser236Ala in the absence or presence of E2. D. 
MI for cAMP-induced ligand independent binding of WT and S305A-ERα to all peptides. E.  MI 
for E2-induced binding (delta) of WT ERα from control and cAMP-stimulated cells (D and E were 
calculated using LIB and LSB, see figure 2).
To illustrate this, we calculated the binding ratio for each peptide of 8-Br-cAMP-treated over 
control samples at a non-saturating EC50 concentration of 4-OH-tamoxifen (Figure 5B).  The 
results demonstrated that PKA-mediated phosphorylation enhances residual binding (ratio>1) 
to the majority of the peptides, suggesting a generally more active ERα under these tamoxifen 
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conditions. This provides a novel mechanism for the previously reported association between 
phosphorylated ERαSer305 and resistance to tamoxifen in breast tumors. It implies that 
patients treated at suboptimal doses of tamoxifen may get tumors escaping tamoxifen control 
by the residual activity of the phosphorylated ERα. 
 The peptides showing increased ERα-binding represent the classical ERα coactivators 
SRC-1/2/3 and nuclear receptor protein 1 (NRIP1, (34)) (IDNR12-21, Figure 5C). Two peptides 
that were unaltered are derived from CREB-binding protein (CBP) and p300 (IDNR3-4).
Figure 5.  Tamoxifen-induced modulation of ERα-coregulator binding.  U2OS cells were transfected 
with ERαY/C wild-type (WT) or ERαSer305A-Y/C (305A).  Cells were stimulated with (+) or without 
8-Bromo-cAMP (cAMP).  A. Dose dependent 4-hydroxy-Tamoxifen (4-OHT)–modulated binding 
to NCOA1_677_700 (IDNR13) by wild-type or ERα305A-Y/C in vehicle or cAMP-stimulated cells. B. 
Binding ratio of 8-Br-cAMP-treated over control samples at a non-saturating EC50 concentration 
of 4-OH-tamoxifen. C.  Dose-response curve  for binding of  of wild-type ERα vs. cAMP-stimulated 
ERα  to coregulator peptides in the presence of 4-OH-tamoxifen.  D.  Binding ratio of cAMP (+) vs. 
vehicle stimulated cells in the presence of 4-OHT at EC50.
Does the peptide array predict patient responses to tamoxifen? 
 We then examined whether Serine 305 phosphorylation is correlated with enhanced 
coregulator binding of ERα from patient material. We selected two breast tumors (A and B) 
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by immunohistochemical evaluation (figure 6B). Both tumors stained positive for ERα and 
tumor B was positive for ERαS305-P, which was confirmed by Western blot (Figure 6C).  ERα 
in the lysates of both these tumors is still responsive to addition of E2, showing increased 
peptide binding on the array (Figure 6D). The role of S305 phosphorylation on receptor activity 
was assessed by dephosphorylation of the receptor in the lysates by addition of lambda 
phosphatase. This treatment largely reduced the level of phosphorylation in the ERαS305-P 
positive tumor B (Figure 6C). For functional analysis on the array, sample input was normalized 
for ERα content measured by ELISA. 
Figure 6.  Functional analysis 
of ERα in crude lysates 
of two breast tumors. A. 
Immunohistochemistry and 
B. Western blot analysis of 
total ERα and ERαSer305-P 
status in the sample of a 
S305P - (tumor A) or  + (tumor 
B) patient before (-) and after 
(+) phosphatase treatment 
of tumor lysates. C. ERα-
coregulator binding profiles of 
tumor A and B after treating 
lysates without (vehicle) 
or with (E2) 17-β-estradiol. 
D. Coregulator binding in 
samples from S305P - or + 
patients, untreated (grey) or 
after phosphatase treatment 
(black). In the absence 
(vehicle) or presence of E2 
(saturating concentration) or 
4-OHT (EC50).
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 Comparison of ERα in untreated lysates (control) of both tumors (grey lines in figure 
6E), showed enhanced binding in the ERαSer305-P positive tumor B (right panel), implying 
increased activity. This was the case for endogenous activity (no ligand added, veh), maximal 
activity at a saturating dose of estradiol and residual activity at EC50 of tamoxifen. This 
enhanced activity in tumor B was strongly reduced by phosphatase treatment of the lysate 
(black lines), whereas the binding levels of the unphosphorylated receptor from tumor A (left 
panel) were unaffected.  Dephosphorylation of ERα in tumor B reduces ligand independent 
activity (vehicle) as well as the response to E2 and the residual activity after tamoxifen (EC50) 
treatment. These data show that serine 305 phosphorylation of ERα, which is associated with 
tamoxifen resistance, can be measured as increased coregulator binding of ERα in clinical 
samples. This assay may therefore be applied for response prediction in the clinic, i.e. enhanced 
ERα activity could be a parameter for drug resistance.
Discussion 
 The application of the peptide array assay as described in this study adds a useful tool 
to gain insight into ERα biology and provides several advantages. 
 It allows the high throughput assessment of ERα binding to multiple NR-boxes. The 
receptor is still functional after sample preparation, reflected by modulation of coregulator 
interaction by reference ligands added on the array. In contrast to reporter and growth assays, 
it directly measures nuclear receptor function instead of its downstream events. The array 
requires minimal sample volumes, which is an advantage when sample volume is limiting, 
e.g. from patient material. We measure ERα activity in crude cell lysates, thereby avoiding 
troublesome purification procedures of full-length receptor. Previous studies report peptide 
binding only to purified fragments of ERα, generally the LBD (27, 28, 31). The analysis of a full-
length ERα more closely reflects what happens in vivo than the LBD. Moreover, the sensitivity 
of the assay allows analysis of endogenous ERα from cells and even from tumor material. The 
binding profiles are minimally influenced by cellular components, which might potentially 
block the peptides by aspecific binding or compete for the coregulator binding pocket of ERα. 
The minor differences we observed in overall binding could be due to differences in sample 
preparation, e.g. isolation of LBD versus crude lysate, the use of different antibodies or the 
presence of tags (CFP/YFP).
 In the presence of ERα antagonist tamoxifen, the receptor adopts a conformation 
that reduces binding of coactivators (35), as is also evident from the binding profiles presented 
in figure 1C/D. Tamoxifen displaced ERα from LxxLL motif-containing peptides on the array 
(Figure 5A, 1C). However, if the cells develop resistance, tamoxifen fails to block growth. In 
this case the interaction between ERα and coactivators, such as NCOA-1 can take place even 
in presence of tamoxifen (22). This is also what we observed upon PKA activation (Figure 4). 
We saw differences on peptides derived from coactivators of ERα that interact directly with 
the receptor: NCOA-1/2/3 and NRIP1. In contrast, no effect was observed on a couple of 
coactivators that can act indirectly on ERα transactivation (CBP and p300) (36, 37).
 Tamoxifen regulates a specific set of genes distinct from E2, suggesting recruitment 
of another transcription machinery with different coregulators (38, 39). However, we did 
not observe specific differences in the binding to LxxLL motifs from directly interacting 
coregulators of ERα as a result of the different treatments. Specific effects may require full-
length coregulators, which contain multiple NR-boxes and potentially interact with both the 
AF-1 and AF-2 domains of ERα.
 We applied the assay to functionally analyze one well-described NR post-translational 
modification: Serine 305 phosphorylation of ERα. which is clinically associated with resistance 
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to tamoxifen (20, 21, 40). Full-length ERα is essential in studying this kind of resistance to anti-
estrogens used in the clinic, because post-translational modifications of ERα outside the LBD 
domain influence the conformation of ERα and thereby the ability of the cofactor interacting 
surface to bind cofactors (11, 41). PKA-activation leads to ERα phosphorylation and enhanced 
receptor binding to the coregulator peptides in a ligand independent manner (Figures 4B and 
5A), and could largely be attributed to ERαS305-P (Figure 4C). The underlying mechanism could 
be the previously reported conformational change of ERα, which would make the cofactor 
binding groove more accessible for the peptides on the chip (42). Coregulator binding by 
ERαS305A mutant was still slightly enhanced by PKA activation (Figure 4C), which means that 
PKA has additional effects on ERα. These effects include a previously reported phosphorylation 
of Ser236 (33). The contribution of phosphorylated Ser236 to enhanced transcriptional activity 
may, however, be limited, since it prevents ERα from binding to its cognate ERE sequence in 
the DNA, whereas ERαS305-P does not hamper binding to DNA (33, 43).
 To extrapolate our findings to the clinic, we selected tumors from two ERα positive 
breast cancer patients, of which one was ERαSer305-P positive.  This parameter correlated with 
enhanced receptor activity in the lysate of this tumor. Upon phosphatase treatment to undo 
ERα phosphorylation, only the receptor from the ERαS305-P positive tumor lost a substantial 
part of its binding capacity. Although this is only a proof of principle on two tumor samples, 
it is striking that the ERαS305-P positive patient had a recurrence of disease after only nine 
months, in spite of tamoxifen treatment, whereas the ERαS305-P negative patient survived 
without recurrence in the follow-up time of 13.5 years.  These current findings in the tumors 
support previous reports that PKA-mediated ERαSer305-P is associated with resistance to 
tamoxifen (20, 21, 40). The enhanced binding to coregulators by ERαS305-P provides a likely 
mechanism for tamoxifen resistance.
 Resistance to endocrine treatment is reflected by enhanced receptor activity in 
a tumor lysate (Figure 6C), so this assay may prove a valuable tool in the future for therapy 
response prediction at an early stage of disease, i.e. immediately after tumor resection and 
before start of adjuvant therapy. Testing the effect on ERα activity ex vivo (e.g. by phosphatase 
treatment of the patient sample) provides clues to the mechanisms of the resistance and may 
add to personalized medicine for breast cancer, e.g. by application of combination therapy 
with a kinase inhibitor.
 In summary, here we present an assay that provides insight in ERα biology and find 
underlying mechanisms for drug resistance. Moreover, functional profiling of ERα may prove a 
valuable tool for clinical purposes, such as prognostics or prediction of treatment response. 
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Abstract
 Protein Kinase A-induced estrogen receptor alpha (ERα) phosphorylation at serine 
residue 305 (ERαS305-P) can induce tamoxifen resistance and growth of breast cancer 
cells. How this phospho-modification affects ERα specificity and translates into tamoxifen 
resistance is unclear. Here we show that S305-P modification of ERα reprograms the receptor, 
redirecting it to new transcriptional start sites, thus modulating the transcriptome. By 
altering the chromatin binding pattern, Ser305 phosphorylation of ERα translates into a 26-
gene expression classifier that identifies breast cancer patients with a poor disease outcome 
after tamoxifen treatment. MYC-target genes and networks were significantly enriched in 
this gene classifier that includes a number of selective targets for ERαS305-P. The enhanced 
expression of MYC increased cell proliferation in the presence of tamoxifen. We demonstrate 
that activation of the PKA signaling pathway alters the transcriptome by redirecting ERα to 
new transcriptional start sites, resulting in altered transcription and tamoxifen resistance.
Introduction
 Breast cancer is the most frequently diagnosed malignancy among women, with 
annually around 1.4 million new diagnoses worldwide. Although treatment has strongly 
improved with the development of adjuvant systemic therapies, still about half a million 
patients die of the consequences of breast cancer (Ferlay J et al., 2010). The choice of adjuvant 
treatment is largely based on the pathological subtype of the breast tumor, which can be 
classified by morphological, molecular and immunohistochemical markers. These subtypes 
correspond to distinct transcriptional repertoires, which translate in a different aggressiveness 
and metastatic potential (Sorlie et al., 2001). 75% of all breast tumors are luminal and proliferate 
dependent on the activity the estrogen receptor α (ERα). Inhibition of ERα by endocrine 
therapy is therefore a major treatment modality of these tumors. Endocrine therapy can be 
subdivided into two treatment modalities; aromatase inhibitors that block synthesis of the 
hormone oestrogen and anti-oestrogens. Anti-oestrogens (including tamoxifen) compete 
with natural oestrogens by occupying the hormone-binding site of ERα and either arresting 
it in the inactive state (Shiau et al., 1998) or inducing degradation of the receptor (Robertson 
et al., 2004). However, patients can acquire resistance to either type of endocrine therapy. 
About 25% of the tamoxifen-treated tumors are resistant to this anti-oestrogen, even though 
the tumor continues expressing ERα (Holm et al., 2009). Consequently, patients unresponsive 
to tamoxifen may still respond to other anti-oestrogens such as faslodex or to aromatase 
inhibitors (Robertson, 2004). A major step in treatment success would be achieved when 
responses to endocrine treatment could be predicted on an individualized basis. Detection of 
ERαS305-P in patient tissues has provided a means of selecting a group of patients resistant 
to tamoxifen prior to the onset of treatment (Bostner et al., 2010;Holm et al., 2009;Kok et al., 
2011). However, full coverage is not achieved and the classification on ERαS305-P signal by IHC 
has to be improved to identify all patients not responding to endocrine therapy due to PKA 
activation.
 Several causes and contributing factors for inducing tamoxifen resistance have been 
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described in breast cancer patients or cell models, including upregulation of growth factor 
receptors (like EGFR (Fan et al., 2007;Massarweh et al., 2008), IGFR and HER2 (Riggins et al., 
2007;Shou et al., 2004)), activation of kinases (such as AKT (Kirkegaard et al., 2005), MAPK 
(Gee et al., 2001;Kato et al., 1995), PKA in combination with PAK1 (Kok et al., 2011;Rayala et 
al., 2006a;Rayala et al., 2006b), and the resulting phosphorylation status of ERα (de Leeuw et 
al., 2011;Michalides et al., 2004;Skliris et al., 2010;Skliris et al., 2009).
 The effects of phosphorylation by PKA of ERα at Serine residue 305 (ERαS305-P) in 
the region between the ligand binding domain and the DNA binding domain are understood in 
molecular detail. Phosphorylation at Ser305 results in a conformational arrest when exposed 
to tamoxifen (Michalides et al., 2004), which affects recruitment of coregulators (Zwart et 
al., 2007). Consequently, tamoxifen acts as an agonist of ERα instead of an antagonist, now 
inducing cell growth of breast cancer cell lines (Dudek and Picard, 2008;Michalides et al., 
2004). An antibody detecting ERαS305-P in tumor sections was successful in identifying breast 
cancer patients with a poor outcome after tamoxifen treatment (Bostner et al., 2010;Holm 
et al., 2009;Kok et al., 2011), translating observations in tissue culture into clinical patient 
responses.
 Since the oestrogen receptor is a nuclear receptor, and its phosphorylation affects 
recruitment of coregulators, the chromatin binding landscape and transcriptome may change 
following this modification. The transcriptome for tamoxifen resistance has been profiled in 
a tamoxifen resistant breast cancer cell line model. Several kinase pathways including PKA 
link to tamoxifen resistance (Dudek et al., 2008;Michalides et al., 2004;Miller, 2002). Several 
classical targets for ERα were differentially regulated including TFF1 (Dudek et al., 2008). PKA 
activation does not only phosphorylate ERα, but has many targets, including coregulators of 
the receptor (Wu et al., 2004;Yi et al., 2008). The phospho-status of coregulators can also affect 
ERα function, thereby indirectly affecting the ERα cistrome and transcriptome (Carascossa et 
al., 2010;Lupien et al., 2009). Other PKA targets may even bypass the receptor and change 
the transcriptome independently. Since kinase activity can alter the chromatin-interaction 
landscape of ERα (Lupien et al., 2010), deciphering a direct connection between ERαS305-P 
modification and direct targets is essential for understanding tamoxifen resistance. Here, 
we aim to define the direct target genes of the modified ERαS305-P and test whether that 
yields predictors for tamoxifen resistance. We determined the resulting transcriptome and 
performed further bioinformatic analyses to determine a predicting gene signature in patient 
material. This signature includes unique ERαS305-P induced pathways that explain tamoxifen 
resistance.
Results
ERαS305 phosphorylation by Protein Kinase A
 To study PKA-induced tamoxifen resistance, we used two well-defined and intensely 
studied breast cancer cell lines MCF7 and MDA-MB134. Both MCF7 and MDA-MB134 express 
ERα and require oestrogens for growth, which is inhibited by tamoxifen (Michalides et al., 
2004;Reiner and Katzenellenbogen, 1986). In MCF7 cells, we activated the PKA pathway by 
forskolin (Al Dhaheri and Rowan, 2007) (Figure 1A top) and isolated RNA for microarray and 
qPCR analyses after 4 hours of tamoxifen exposure to probe early transcriptional responses 
of ERαS305 phosphorylation. Forskolin treatment induces phosphorylation of ERαS305 
as detected by a specific antibody (Figure 1B top). While we chemically activated the PKA 
pathway in MCF7 cells, we decided to confirm results by genetically activating this pathway 
in MDA-MB134 cells. Here, PKA was activated by silencing the inhibitory subunit of PKA, 
PKA-RIα (Figure 1A bottom) (Bossis and Stratakis, 2004), which is also observed in tamoxifen-
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resistant patients (Michalides et al., 2004). When PKA-RIα is silenced, PKA is activated yielding 
phosphorylation of ERαS305 (Michalides et al., 2004). Silencing PKA-RIα was confirmed by 
Western blot analysis (Figure 1B bottom). In addition, increased phosphorylation of PKA 
substrate CREB confirms that PKA is activated in both cell lines (Figure 1B), yielding an elevated 
ERαS305-P signal.
Figure 1: ERαS305 phosphorylation 
by Protein Kinase A. A. Experimental 
setup to activate PKA in MCF7 
(top) by forskolin stimulation and in 
MDA-MB134 (bottom) by PKA-RIα 
knockdown with lentiviral shRNA. 
Dissociation (MCF7) or loss (MDA-
MB134) of PKA-RIα liberates the 
active, catalytic subunit of PKA, 
leading to ERαS305 phosphorylation. 
B. Western blot analysis of the model 
systems. Top: Forskolin treatment of 
MCF7 cells leads to activated PKA, 
illustrated by increased p-CREB, and 
elevated ERαS305 phosphorylation. 
Bottom: shRNA approach successfully 
decreases PKA-RIα level in MDA-
MB134 cells, leading to increased 
p-CREB and ERαS305-P.
A gene signature for tamoxifen resistance after PKA activation
 We analyzed the effects of PKA-induced ERαS305 phosphorylation on the 
transcriptome by expression microarray analyses. Under conditions corresponding to the 
experiments above (Figure 1), cells were deprived of hormones for three days and subsequently 
treated with tamoxifen, after which the influence of PKA activation was assessed in both cell 
lines (Figure 2). PKA was chemically activated in MCF7 cells and genetically in MDA-MB134 
cells. Gene expression distribution is illustrated by the log-ratio, for PKA-activated versus 
non-activated cells, over intensity (RI) dot plots (Figure 2A). In MCF7 cells, we identified 152 
upregulated and 108 downregulated genes following PKA activation (260 in total). In MDA-
MB134, we find 385 up- and 437 downregulated genes (822 in total). In these gene expression 
profiles, 59 up- and 41 downregulated genes overlap between MCF7 and MDA-MB134 (Figure 
2B). By focusing on the overlap of 100 differentially regulated genes, we eliminated cell 
line or treatment-specific effects. Among the upregulated hits are two classical targets for 
estradiol-stimulated oestrogen receptor: TFF1 and XBP1, the latter of which is in the top 5 
of differentially regulated genes. The top 10 up- and downregulated hits for MCF7 cells are 
indicated (Figure 2C), and a subset tested and confirmed by qPCR (Figure 2D). Next, we tested 
the 100 differentially regulated genes that are shared between the two cell lines and conditions 
(59 up, 41 down) as a classifier to identify ERα-positive breast cancer patients responding 
poorly to tamoxifen treatment, using a publically available dataset (Loi et al., 2007). The gene 
classifier was found to significantly correlate with poor outcome after tamoxifen treatment 
(p=0.019; hazard ratio=2.5) (Figure 2E top). This classifier was validated in an independent 
patient series (Buffa et al., 2011), again identifying the patients with a poor outcome after 































Figure 2: Gene signature 
for tamoxifen resistance 
through PKA activation
A. RI-plots of microarray 
profiles of MCF7 (left) and 
MDA-MB134 (right). Log-
ratio is plotted over intensity. 
For further analysis, a 
threshold is used of >1.5x 
difference (log-ratio = 0.585), 
indicated by the red line, and 
p<0.05.
B. Venn diagrams of up- 
(top) and downregulated 
(bottom) genes show overlap 
between MCF7 (purple) and 
MDA-MB134 (orange) gene 
expression signatures.
C. Table of the top 10 
of up- and downregulated 
genes ranked on MCF7 
mRNA expression values. 
Genes represented in red (up) 
or green (down) are tested 
and confirmed by qPCR as 
illustrated in:
D. qPCR validation of a 
subset of the top hits. mRNA 
expression relative to house-
keeping gene β-Actin. MA 
= Microarrays values. Error 
bars represent standard 
error of the mean (SEM). * p 
< 0.05 by Student’s t-test.
E. Genes shared between 
MCF7 and MDA-MB134 are 
combined into a 100-gene 
signature. This signature was 
applied as a gene classifier 
in a disease metastasis 
free survival analysis. The 
average gene expression 
values in ERα positive, 
endocrine treated patients selected from Loi et al. (top, (Loi et al., 2007)) and Buffa et al. (bottom, 
(Buffa et al., 2011)) were calculated and ranked for up- and downregulated genes. Patients were 
stratified as described in the materials and methods. Patients who have a positive signature for the 
classifier show significantly worse disease progression (Loi data: p=0.019; hazard ratio(HR)=2.5; 















































































































S305P modification of ERα targets the receptor to promoters
 PKA activity results in the phosphorylation of many targets, including ERα. ERα itself 
has two target sites for PKA, Serine 236 (Chen et al., 1999) and Serine 305, which is predominant 
and also correlates to tamoxifen resistance (Michalides et al., 2004). To determine the effects 
of ERαS305 phosphorylation on gene transcription and chromatin deposition, we analyzed the 
chromatin-binding landscape of ERαS305-P by means of ChIP-seq with a specific monoclonal 
antibody (Holm et al., 2009). To this purpose, cells were cross-linked, chromatin fragmented 
and ERαS305-P immunoisolated. The co-isolated chromatin fragments were amplified, 
sequenced and mapped against the human genome reference (Figure 3A) (Schmidt et al., 
2009). MCF7 cells were hormone deprived for three days and stimulated with forskolin. Since 
transcriptional alterations were observed four hours after tamoxifen treatment, the chromatin 
interaction patterns of ERαS305-P were studied at an earlier time point (two hours of forskolin 
treatment) as DNA binding precedes transcription. ERαS305-P binding patterns were compared 
to chromatin interactions of total ERα from asynchronously proliferating MCF7 cells (Robinson 
et al., 2011) to determine the shared events and unique binding sites for the phosphorylated 
receptor. ERαS305-P shows 2657 binding events, of which 947 overlap with total ERα (Figure 
2C and D). This implies that S305-phosphorylated ERα shares only a subset of the conventional 
ERα binding sites, but also has its own specific targets sites. Examples of shared and unique 
sites are shown in Figure 2B. When the binding peaks were annotated, a striking enrichment 
for ERαS305-P was observed for promoter regions, 3’UTRs and 5’UTRs, whereas total 
ERα generally prefers distal enhancers (Figure 3E), as was described before (Carroll et al., 
2006;Madak-Erdogan et al., 2011). This enrichment on promoter regions is not only observed 
for the shared interaction sites, but also for unique ERαS305-P peaks. Consequently, DNA 
motif analyses of ERα and ERαS305-P reveal different motifs concurrent with differences in 
the transcriptome (Figure 3F, shown are some genes identified in the microarray analyses in 
Figure 2). Modification of ERα at Ser305 not only affects ERα conformation (Michalides et al., 
2004) but also chromatin binding sites, transcription and cellular responses.
Interconnection of genes in the classifier 
 To understand how phosphorylation of ERαS305 drives differential gene expression, 
resulting in tamoxifen unresponsiveness of breast tumors, we decided to define the functional 
networks that are differentially (in)activated due to the modification of ERα. An Ingenuity 
Pathway Analysis (IPA) of the differentially regulated genes in both conditions was performed, 
which identifies functional connections from a gene list using literature data. Within the top 
pathways listed in Figure 4A, classical ERα targets (TFF1, XBP1, CAV1) as well as interacting 
partners of ERα for non-classical gene transactivation, such as AP-1 and NFκB (Suppl. Figure 
S1) were found, illustrating expected ERα-mediated gene expression rather than only PKA 
activation.  
 PKA-activation can induce cell growth in tamoxifen-stimulated breast cancer cells 
(Dudek et al., 2008;Michalides et al., 2004). We therefore focused on the third network, which 
links genes in the classifier to cell growth and proliferation. This network includes MYC as a 
central player (Figure 4B). MYC is not a direct hit in our microarray analysis as it was enriched 
just below the threshold (1.49x) in MCF7 cells. We validated elevated MYC expression in MCF7 
cells following forskolin and tamoxifen stimulation by a more quantitative method: qPCR 
(Figure 4C). PKA activation combined with tamoxifen treatment upregulates MYC expression 
1.65-fold, directly coupling ERαS305 phosphorylation to expression of a well-known oncogene 
involved in tamoxifen resistance (Miller et al., 2011;Musgrove et al., 2008). Of note, the effect 




Figure 3: Distinct chromatin binding patterns 
of ERαS305-P 
A. Experimental setup: after 2 hours of 
forskolin stimulation, ChIPseq is performed 
using a specific antibody against ERαS305-P.
B. Examples of chromatin interaction 
to two gene areas for total ERα (green) 
and S305-phosphorylated ERα (blue). 
Retinoic acid receptor alpha (RARA) has 
an ERα binding site within a 20k nucleotide 
region of the transcription start, to which 
ERaS305-P also binds. S100P shows binding 
for both total and phosphorylated ERα, but 
ERαS305-P prefers the promoter, whereas 
total ERα binds to a distal enhancer. Arrows 
denote binding peaks. A 5 kb size marker is 
indicated.
C. Venn diagram, showing the overlap 
of ERαS305-P (blue) chromatin binding 
events  versus total ERα (green). Number of 
shared or unique peaks are indicated. Called 
peaks were interrogated for overlap and 
intersected using Galaxy (http://main.g2.bx.
psu.edu/).
D. Genomic distribution of overall 
ERαS305-P binding (left), total ERα (right) 
and sites shared between the two (middle). 
The genomic distributions of binding sites 
were analyzed using the cis-regulatory 
element annotation system (CEAS) (Ji et 
al., 2006). The genes closest to the binding 
site on both strands were analyzed. If 
the binding region is within a gene, CEAS 
software indicates whether it is in a 5’UTR, a 
3’UTR, a coding exon, or an intron. Promoter 
is defined as 1 kb upstream from RefSeq 5’ 
start. If a binding site is >1 kb away from 
the RefSeq transcription start site, it is 
considered distal intergenic. ERαS305-P 
shows preference for promoter sites.
E. Motif analysis of binding sites 
for ERαS305-P (blue) and total, estradiol-
stimulated ERα (green) show a difference in 
motif preference. To identify motifs, SeqPos 
was used (He et al., 2010). SeqPos use the 
distances from motif positions to the peak 
summits (center of the regions) to find the 














































































Figure 4: Interconnection 
of genes in the classifier
A. Ingenuity pathway 
analyses reveal direct and 
indirect links between the 
genes in our classifier, 
resulting in the top 5 of 
significant pathway terms 
listed in the table and 
shown in Supplementary 
Figure 1. Networks are 
scored based on the 
number of network eligible 
genes the list contain 
contains. Score is a 
likeliness parameter.
B. Shown is network 3 as 
shown in bold in Figure 
4A. MYC plays a key role, 
targeting several of the 
genes from the classifier. 
Differential expression in 
the microarray in Figure 2 
is illustrated by a red (up) 
or green (down) color. The 
nature of the different hits 
is indicated on the right.
C. MYC qPCR of MCF7 
cells after 4 hours of 
treatment with estradiol 
(E2), tamoxifen (TAM) or 
hormone depleted (ctrl) 
in presence or absence of 
forskolin to stimulate PKA. 
Error bars represent SEM. 
* p < 0.05 by Student’s 
t-test.
Integration of ERαS305-P chromatin binding with gene expression signatures 
 Selective ERαS305-P interactions with chromatin should translate into transcriptional 
differences. To assess these, we integrated the ChIP-seq data with the expression data obtained 
from the microarray studies. This allowed us to extract the direct targets of ERαS305-P from 
the bulk of genes that are differentially regulated due to overall PKA activation. Among the 100 
hits from our classifier, we defined the genes that had a chromatin binding peak for ERαS305-P 
within a 20k region from the transcription start site, which indicates direct transcriptional 
regulation by the receptor (Fullwood et al., 2009). This identified 26 genes as direct targets of 
ERαS305-P. 14 of these genes were upregulated and 12 downregulated (Figure 5A). Of these 
direct ERαS305-P targets, nine are distinct from estradiol-stimulated, total ERα, implying 
Associated Network Functions Score 
1 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 50 
2 Cell Signaling, Nucleic Acid Metabolism, Small Molecule Biochemistry 39 
3 Cell Cycle, Cellular Development, Cellular Growth and Proliferation 32 
4 Lipid Metabolism, Small Molecule Biochemistry, Cellular Movement 24 
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that they are specific for the phosphorylated form. Utilized as a classifier in the previously 
mentioned patient dataset by Loi et al. (Loi et al., 2007), the 26 ERαS305-P targets result in 
a significant correlation with poor disease outcome (Figure 5B. p=0.008 ; HR=2.33). Applying 
the classifier to the Buffa et al. (Buffa et al., 2011) dataset, the number of patients became too 
small for a reliable analysis. 
 When separately analyzing the direct ERαS305-P targets versus the non-
phosphorylated ERα by qPCR, we observed a ligand independent effect for PKA activated 
genes that do not have a chromatin binding site for ERαS305-P (Figure 5C). This in contrast 
to the majority of the tested genes with a proximal ERαS305-P binding site, where tamoxifen 
exposed an additional agonistic behaviour next to the effects of PKA stimulation alone (Figure 
5C).
 We then analyzed the new classifier for biological relevance. Seven of the 26 direct 
targets are functionally connected with MYC, implying that ERαS305-P directly affects the 
MYC pathway (Figure 5D), rather than upregulating Myc only. Since MYC was upregulated 
in the PKA-activated, tamoxifen-treated MCF7 cells, we explored whether MYC is a direct 
target of ERαS305-P. To this end, the proximity of the Myc locus was analyzed for ERαS305-P 
peaks. We observed a chromatin interaction peak at a distal enhancer that has been recently 
described for ERα in synergy with AP-1 (Wang et al., 2011) and a second peak at the promoter 
region of MYC (Figure 5E, arrows denote the peaks). Taken together, we show by ChIP-seq, 
microarray and qPCR that S305-phosphorylated ERα plays a direct role in MYC transcriptional 
regulation. Myc upregulation will affect cell growth in response to tamoxifen.
 To directly assess the influence of MYC on MCF7 cells proliferation, and the influence 
of tamoxifen treatment thereon, MYC was transiently overexpressed in MCF7 cells (quantified 
in Figure 5G). This resulted in a significant increase in cell proliferation both in absence and 
presence of tamoxifen (Figure 5F), linking the enhanced expression of MYC with cell growth 
even in presence of this anti-estrogen and thus inducing resistance.
Discussion
 Activation of kinase pathways is one of the hallmarks of tumor formation. Most 
breast cancers are critically dependent on ERα and this nuclear hormone receptor can be 
modified by a series of kinases, including PKA (Gee et al., 2001;Kato et al., 1995;Kirkegaard 
et al., 2005;Michalides et al., 2004;Rayala et al., 2006a). PKA phosphorylates ERα at position 
305, inducing a conformational arrest of the receptor upon tamoxifen exposure (Michalides 
et al., 2004). This eventually results in tamoxifen resistance and cell proliferation in response 
to tamoxifen exposure (Dudek et al., 2008;Michalides et al., 2004). However, the exact 
mechanism of tamoxifen resistance remains unknown and this is studied here. We show that 
S305-P modification has a marked effect on the accurate positioning of ERα on transcriptional 
start sites. This is highly surprising and, in more general terms, suggests that post-translational 
modifications can have major effects on chromatin binding of transcription factors and thus 
the transcriptome. In fact, this couples extracellular signalling (in our case by PKA activation) to 
alterations in transcriptional output by a retargeting of the transcription factor to alternative 
binding regions.
 The phosphorylated receptor displayed an enrichment for DNA motifs that were 
distinct from that of total ERα in proliferating cells, suggesting that the phosphorylation 
directly alters the DNA binding capacities of specificity of the receptor. The crystal structure 
data of the full length RXR:PPARγ heterodimer shows an alignment of the hinge region of 
PPARγ along the DNA (Chandra et al., 2008).  This may also occur with the hinge domain of 
ERα, thereby determining the DNA motif specificity of the receptor. 
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Figure 5: Integration of ERαS305-P 
chromatin binding and gene 
expression signatures 
A. Hierarchical clustering of the 
100 genes in the classifier, based 
on ERαS305-P chromatin binding, 
estradiol-induced chromatin 
interactions and gene expression of 
total ERα. 
B. The 26 ERαS305-P hits were 
applied as a classifier on the patient 
dataset derived from Loi et al. (Loi et 
al., 2007), resulting in a significant 
correlation with poor disease 
outcome (p=0.008 ; HR=2.33 ). 
Analysis was performed as described 
in Figure 2D.
C. Scatter plot for qPCR data 
from genes upregulated by PKA 
activation, derived from the 100-
gene classifier and subdivided into 
two groups: with (blue diamonds) 
or without (red squares) a proximal 
binding site for ERαS305-P. Ratio for 
PKA activation over no activation 
is plotted for presence (Y-axis) or 
absence (X-axis) of tamoxifen. 
Diagonal line represents equal ratios 
irrespective of tamoxifen. 
D. Six (representing 23%) of the direct 
targets are found in the MYC-related 
Ingenuity network, highlighted in 
orange. 
E. ERαS305-P selectively targets 
MYC by binding to a distal enhancer 
and the promoter. Shown are the 
reads for ERα and ERαS305-P around 
the MYC gene and the 20kb marker. 
Arrows indicate the two peaks.
F. MYC overexpression enhances 
tamoxifen-specific MCF7 cell growth. 
Absolute cell numbers of triplicates 
are counted and plotted for YFP-
control (ctrl in blue) and MYC (in red). 
In triplo, scale bars = standard error of 
the mean (SEM) A student T-test was 
performed; p=0.03.
G. c-Myc protein expression analysis 
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 Any modifications in the hinge domain (including S305 phosphorylation) may, as 
a consequence, alter the DNA-binding preferences of the receptor. The altered positioning 
of ERα when phosphorylated at S305 is surprising but unlikely to be dictated by this post-
translational modification alone. Most likely, the S305-P modification attracts different co-
factors that in assembly alter the chromosome-binding preferences of the receptor. Such 
effects can be mediated further by phosphorylation of CARM1 (Carascossa et al., 2010) or AIB1 
(Yi et al., 2008),  but may also be dictated by other factors. ERα binding events are not rigid, 
but can differ between cell lines (Krum et al., 2008) and the chromatin-binding pattern can be 
manipulated by growth factor stimulation (Lupien et al., 2010). To our knowledge, this is the 
first report describing the direct effect of phosphorylation on the chromatin binding landscape 
of ERα. The distinct and unique patterns as observed here suggest that phosphorylation events 
on the receptor not only dictate the transcriptional readout (Michalides et al., 2004), the 
transcript repertoire (Dudek et al., 2008) and cofactor preferences (Zwart et al., 2007), but also 
determine to what DNA regions the receptor is capable of binding. This yields a complicated 
view on transcriptional regulation by ERα. As this protein can be modified at different locations 
by different kinases, different chromatin deposition and thus transcription may be the result. 
Depending on the activated signalling pathway, a different DNA binding preference of ERα 
after oestrogen activation or tamoxifen exposure may be the result. 
 We show here for the S305 modification that distinct transcriptional pathways are 
generated that can explain cell growth of breast cancer cells in response to tamoxifen. This 
is visualized in the development of a classifier that allows prediction of patient’s responses 
to tamoxifen treatment. Further analyses show that the MYC pathway in particular can be 
activated, which may explain the more aggressive behaviour of such tumours.
 Our data illustrate that one single post-translational modification can have a major 
impact on the chromatin interaction patterns and transcriptome of the oestrogen receptor. 
ERαS305 phosphorylation greatly affects its DNA-binding sites, giving rise to distinct 
responsive gene signature that includes MYC and its related genes. MYC overexpression 
overcomes tamoxifen action on cell proliferation and hence, a PKA-induced elevation of 
MYC would induce resistance to tamoxifen. The plasticity in the chromatin binding patterns 
of ERα as induced by PKA activation has significant downstream effects that may lie at the 
very basis of tamoxifen-resistance of breast cancer patients. The genes differentially targeted 
and transcribed by S305-phosphorylated ERα indeed act as a biologically relevant and 
understandable classifier for breast cancer patient responses to tamoxifen treatment.
Materials and Methods
Cell culture
 MCF7 and MDA-MB134 cells were cultured in DMEM supplemented with 8% FBS 
and antibiotics (penicillin, streptavidin). To deprive cells of hormones, they were cultured in 
phenol-red free DMEM with 5% charcoal-treated serum and antibiotics. Cells were stimulated 
with 10-7 M 4-OH-tamoxifen and/or 10mM forskolin or vehicle for 4 or 24 hours.
PKA-RIα knockdown
 MDA-MB134 cells were infected with lentivirus containing a shRNA (sequence: 
GGGGATAACTTCTATGTGA) targeting PKA-RIα. Infection was performed in DMEM after 
2h incubation with polybrene (5ug/ml). After infection overnight, DMEM with 8% FBS was 
refreshed. Selection of infected cells was done with 3 mg/ml puromycin.
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 Western blotting was performed according to standard protocols. Antibodies used 
are anti-ERα (Santa Cruz Biotechnology), anti-ERαS305-P (Millipore/Upstate), anti-b-Actin 
(Millipore/Chemicon), anti-p-Creb (Cell Signaling Technology), anti-PKA-RIα (BD Transduction 
Laboratories) and anti-c-Myc (Santa Cruz Biotechnology). Signals were detected with a Lumi-
light Plus detection kit (Roche).
Microarray experiments
 Cells were harvested and homogenized in trizol (Invitrogen). RNA was isolated 
and hybridized on IlluminaWG-6 expression BeadChip (MDA-MB-134) and Human HT-
12 v4 Expression BeadChip (MCF7, performed in triplicate). For data extraction, we used 
no background correction, applied variance stabilizing transformation and robust spline 
normalization. Data were log-transformed, ratios of the absolute values were calculated. 
For the RI plots, the log-ratio was plotted over the intensity, calculated from the absolute 
intensities as follows: R = log (PKA-activated / control) and I = log (PKA-activated x control). 
P-values absolute-value ratios were calculated with a two-tailed paired t-test. Hits were 
selected on p<0.05 with a ratio threshold of 1.5x.
Bioinformatics patient datasets
 We extracted the ERα positive, tamoxifen treated tumors from two published patient 
datasets (Buffa et al., 2011;Loi et al., 2007). All the expression data were retrieved for the 100 
hits in the classifier. The average expression of all the tested genes was calculated, ranked and 
divided in two groups. Patients were stratified in two groups: 1. upregulated genes in the top 
50% and the downregulated genes in the bottom 50%. 2. upregulated genes in the bottom 
50% and the downregulated genes in the top 50%. Kaplan-Meijer plots were generated using 
Prism 5 (Graphpad software). P-values were calculated using a log-ranked Gehan-Breslow-
Wilcoxon method.
qPCR
 Cells were harvested and homogenized in trizol. RNA isolation for qPCR was 
performed by a phenol-chloroform extraction. cDNA was made with a Superscript III RT 
kit (Invitrogen) using the manufacturer’s protocols. qPCR was performed with SYBR Green 
(Applied Biosystems) on a Chromo4 RT detector (Bio-Rad) using standard protocols. Primers 
(Invitrogen) were designed with primer3 v0.4.0 and are shown in Supplementary table 4.
ChIP-seq
 ChIP experiments were performed as described previously (Carroll et al, 2005). The 
antibody used was anti-ERαS305-P (Millipore/Upstate). ChIP DNA was amplified as described 
(Schmidt et al., 2009). Sequences were generated by the Illumina GAIIx genome analyzer 
(using 36-bp reads), processed by the Illumina analysis pipeline version 1.6.1, and aligned to the 
Human Reference Genome (assembly hg18, NCBI Build36.1, March 2008) using BWA version 
0.5.5. Reads were filtered by removing those with a BWA alignment quality score less than 15. 
For each biological replicate, a corresponding set of input sequence reads of similar size was 
obtained by random sampling from the full set of input sequence reads. Enriched regions of 
the genome were identified by comparing the ChIP samples to input samples using the MACS 
peak caller (Zhang et al., 2008) version 1.3.7.1. All ChIP-seq data was from intersected peaks, 
shared between two independent replicates.
MYC overexpression and cell proliferation assay
 MCF7 cells were cultured in 12-wells plates. After one day of hormone deprivation, 
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MYC was overexpressed by polyethylenimine (PEI, Polysciences (Boussif et al., 1995)) 
transfection of a RC-CMV c-Myc vector. A pcDNA-YFP empty vector was used as control. Cells 
were treated in triplicate with estradiol (10-8M), tamoxifen (10-7M), fulvestrant (ICI, 10-7M) or 
control for 7 days. After trypsinization, cells were counted with a CASYton cell counter (Casy 
Technology). 
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Supplementary Figure S1:  Networks derived from the Ingenuity analysis presented in Figure 4A
Supplementary Figure S2: qPCR data for Figure 5C, in triplo, scale bars = SEM, *p<0.05.
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Supplementary Figure S2 - qPCR data for Figure 5C




































Summary & discussion 
 About 70% of all breast cancers express the estrogen receptor and are dependent on 
estrogens for tumor cell proliferation. These patients commonly receive endocrine therapy, 
which includes two different classes of drugs: aromatase inhibitors and antiestrogens. These 
two classes have different mechanisms of action to establish the same effect: blockage of 
estrogen-dependent growth of tumor cells. Aromatase inhibitors prevent estrogen synthesis, 
hence depriving the receptor of natural ligand. Antiestrogens block the estrogen receptor by 
binding to the ligand binding pocket, thereby competing with the natural ligand and inactivating 
the receptor. This thesis focuses on the antiestrogen most applied in the clinic, tamoxifen, with 
which many patients have been treated successfully (1). However, not everyone benefits from 
this form of endocrine treatment and develop a recurrence (2, 3). To understand resistance 
to tamoxifen in breast cancer patients, there is a need to explore the underlying molecular 
biology and translate this knowledge into biological and clinical relevance. 
 Because tamoxifen acts directly on the estrogen receptor, it is imperative to study 
its function and the alteration thereof when drug resistance occurs. In Chapter 2, we set out 
to explore the different subdomains the receptor consists of and how these domains regulate 
processes upon ligand binding. The estrogen receptor family consists of two members, 
estrogen receptor alpha (ERα) and beta (ERβ). Estrogen receptor positivity in breast cancer 
generally refers to the ERα subtype. ERα and ERβ differ in classical and non-classical gene 
transactivation and cofactor-binding capacity (4-6). We compared ERα and ERβ to better 
understand the individual contributions of distinct domains of the receptor on ligand responses. 
Between the two receptors, the DNA binding domain is highly conserved (93%) and can 
interact with the classical estrogen responsive element (ERE) on the chromatin to induce gene 
expression. The ligand binding domain is only 53% conserved between the two members of 
this family, which may explain that subsets of ligands exist that are specific for either for ERα 
or ERβ (7). This does however not explain the fact that ERα and ERβ can respond differently to 
shared ligands such as tamoxifen and estradiol (8). In Chapter 2, we demonstrate that these 
differences are determined by the activation function domain 1 (AF-1) and hinge region that 
are largely dissimilar between ERα and ERβ. We swapped these domains between ERα and ERβ 
and thereby affected estrogen receptor structure, as demonstrated by intramolecular FRET 
changes. Swapping the hinge or AF-1 domain at least partially switches ER subtype specific 
behavior in terms of the ERα distinct AF-1 binding of coregulator SRC-1, recruitment of the 
transcription machinery RNA polymerase II (i.e. before or after ligand binding), subsequently 
influencing gene transactivation on an estrogen responsive element (ERE). It also switches the 
effect on gene transactivation in a reporter assay with a non-classical AP-1 motif. The hinge 
and AF-1 domains appear to act in synergy with AF-2 to determine estrogen receptor function. 
Nonetheless, some questions remain. The ultimate control for this mechanism that has not 
been addressed is a combined swap of the AF-1 and the hinge region, or alternatively the AF-2 
domain alone, which in essence would be the same. The expected outcome of this experiment 
would be a complete swap in estrogen receptor function for ligands shared between ERα and 
ERβ, but not for distinct ligands: ERα needs both the active AF-1 and the longer flexible hinge 
for its full E2-induced response. Swapping only a small region of the hinge is not sufficient, even 
though this is a region in ERα that is prone to post-translational modifications and thereby a 
central node for estrogen receptor function. These post-translational modifications, including 
S305 phosphorylation, affect ERα function, but do not influence ERβ function upon swapping. 
Still, a conformational change is detected with intramolecular fluorescence resonance energy 
transfer (FRET). This technique allows assessment of the orientation of the AF-1 and AF-2 
domain, by tagging the estrogen receptor with a donor fluorophore on one terminus and 
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an acceptor on the other. When the conformation changes and the two ends come closer 
together or alter their orientation, the donor may transfer energy to the acceptor fluorophore, 
which consequently emits light (9). Although FRET detects a conformational change with the 
small hinge swap, the lack of effects on transcription could be due to the shorter, more rigid 
hinge of ERβ, leaving less room for proper positioning of AF-1 and AF-2 to recruit coregulators 
and bind chromatin. This means that in this case, FRET is not indicative of downstream gene 
transactivation.
 The ratio between ERα and ERβ may be of relevance in how breast cancer responds 
to endocrine treatment: ERβ has been described to block estrogen dependent growth (10). 
When the estrogen receptor binds a ligand, it dimerizes, enters the nucleus and binds to the 
chromatin to induce gene expression. It not only forms homodimers (ERα:ERα and ERβ:ERβ), 
but also heterodimers (ERα:ERβ) (11). This could imply a different function, and indeed, both 
ERβ homodimers and ERα:ERβ interfere with E2-driven proliferation of breast cancer cells. 
Because the DNA-binding domain is 96% conserved, the chromatin binding landscape should 
be the same, unless other regions play an additional role in estrogen receptor positioning. The 
crystal structure of a more distant ER family member, the heterodimer PPAR:RXR  reveals that 
the C-terminal helix of PPAR positions itself along the DNA, suggests a role in its chromatin 
interaction (12).  This could mean that the C-terminus of the estrogen receptor may also play 
a synergetic role with its DBD in chromatin binding. Nonetheless, one report describes that 
the vast majority of chromatin binding sites of ERβ are shared with ERα (13). It might still be 
interesting to compare the chromatin binding landscape of ER heterodimers and homodimers 
by re-ChIP-seq experiments to test whether they have distinct chromatin binding specificity. 
However, the dissimilarities in behavior of the two estrogen receptor subtypes do not seem 
to be caused by differential DNA interactions. More likely, the differences in AF-1 domain and 
hinge region influence the structural conformation of the receptor and thereby determine 
which coregulators are recruited. 
 We addressed the recruitment of coregulators by ERα in Chapter 3. This is the first 
report in which a high-throughput approach for coregulator binding to full length, endogenous 
estrogen receptor is applied. This approach consists of an array with coregulator peptides 
containing a motif for nuclear receptor binding: the LxxLL motif. We found that the peptide 
binding profile of full length, estrogen-bound receptor on the array highly resembles the profile 
that was observed for the ligand binding domain alone.  Moreover, tagged, overexpressed or 
endogenous protein behaves very similar, suggesting that these differences have no substantial 
effect on coregulator peptide binding and estrogen receptor functionality. Measurements for 
endogenous protein were performed in MCF7 cells, whereas overexpression was done in U2OS 
cells that do not endogenously express the estrogen receptor. The difference in cell context 
did not affect the peptide binding profile. As expected, ligands have an impact on the cofactor 
interaction: estradiol induces stronger binding of coregulators, whereas tamoxifen reduces 
this interaction. After having established the applicability of this peptide array for testing 
estrogen receptor function, we addressed its application as a system to monitor tamoxifen 
resistance. One mode of tamoxifen resistance is ERα phosphorylation at Serine 305 (S305), as 
induced by protein kinase A (PKA) (14-16). S305 phosphorylation induces a structural change of 
ERα, altering the orientation between the receptor and its coactivators SRC-1, allowing SRC-1 
to bind not only to the AF-1 but also the AF-2 domain of ERα. Consequently, the transcription 
machinery becomes active when tamoxifen is bound (17). The PKA-induced conformational 
change of ERα potentially affects orientation and strength of binding to other coregulators, 
affecting DNA interaction and induction of transcription of responsive genes, which ultimately 
results in an increased cell proliferation. Hence, tamoxifen will act as an agonist when 
ERαS305 is phosphorylated (18). On the peptide array, we also detected stronger coregulator 
97
interactions with a tamoxifen-bound, S305 phosphorylated estrogen receptor, indicating a 
more active ERα in a tamoxifen resistant setting.
 We did not observe obvious coregulator specific differences. Estradiol treatment or 
S305 phosphorylation by PKA seems to elevate coregulator binding for all peptides that already 
interact with ERα ligand, rather than specific ones. Moreover, the conformational change 
upon ligand binding or phosphorylation of the receptor does not induce new interactions 
with other peptides. This implies that the conformation as such does not determine binding 
to distinct coregulator motifs, but other factors appear to determine specificity. In order to 
achieve specificity, a full length coregulator may be required. ERα is known to interact with 
SRC-1 with both the AF-1 and AF-2 domains. The AF-2 domain binds an LxxLL motif, whereas 
the AF-1 domain interacts with a Q-rich region on SRC-1 (17). This second interaction could not 
be detected in our peptide assay, because the peptides only include the LxxLL(-like) motifs 
and not the Q-rich region. Since this interaction may be essential for specificity in coregulator 
recruitment, the overall, rather than peptide specific, increase in binding may simply be due to 
more efficient exposure of the AF-2 coregulator binding surface of ERα upon estradiol-binding 
or phosphorylation at S305.
 Nonetheless, the stronger binding to the LxxLL-coactivator motifs is indicative of a 
more active ERα. It is striking that we can detect this effect with one single post-translational 
modification: S305 phosphorylation. There is no need to isolate the receptor and in fact using 
cell lysates avoids an intricate and troublesome process of isolation, with the risk of loss of 
phosphorylation. Even in tumor cell lysates, we were able to detect an increased ERα function, 
when S305 is phosphorylated as validated by immunohistochemistry. It is important to realize 
that such a biochemical assay is likely to expose a lower-detection threshold, which still needs 
to be determined. As a direct consequence, this approach may not prove useful for tumors with 
low staining and few S305-P positive cells as any positive signal will be diluted by the normal 
tumor. What could aid in improving detection is extracting tumor cells from surrounding 
stroma and normal cells, which would concentrate the (phosphorylated) estrogen receptor in 
the sample. Such technical hurdles should be addressed in a more extensive study to assess 
the applicability of this assay in a clinical setting.
 A stronger overall binding of ERα from patient material to the peptide array would 
imply a higher basal activity of the estrogen receptor, which could be an indication of resistance 
to tamoxifen. The coregulator peptide array, detecting ERα function, may be of added value in 
predicting tamoxifen response in patient material. Stronger binding of the estrogen receptor 
implies that it is phosphorylated, thereby resistant to the drug. This assay, however, needs 
further testing for clinical application.
 Thus far, we have shown that ERαS305 phosphorylation elevates coregulator binding 
to ERα when associated to tamoxifen. In the clinic, tamoxifen resistance caused by PKA-
induced phosphorylation of ERαS305 is correlated with poor outcome in estrogen-receptor 
positive, tamoxifen-treated breast cancer patients (14-16). What was still unresolved is how 
a phosphorylated receptor, possibly by inducing better coregulator binding, ultimately leads 
to tumor cell proliferation.  In Chapter 4, we addressed this gap in understanding of this form 
of tamoxifen resistance by an integrative analysis of the chromatin binding landscape and 
the resulting transcriptome from ERα phosphorylated by PKA. This single post-translational 
modification has a striking effect on the chromatin binding landscape of the estrogen receptor: 
whereas generally ERα prefers distal enhancers, ERαS305-P is redirected to promoter regions, 
5’ and 3’ UTRs. This is the first report demonstrating that one single post-translational 
modification of ERα can have major impact on the chromatin binding landscape. With this 
novel finding, it is imperative to interrogate other post-translationally modifiable sites for 
ERα, e.g. by acetylation (19), and compare the results to our findings for ERαS305-P to define 
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the consequences of the ‘ER modification landscape’.
 The transcriptome of ERαS305-P with tamoxifen was studied by PKA-activation in 
breast cancer cells. MCF7 is a commonly used model breast cancer cell line, which we treated 
with a chemical (forskolin) to induce PKA activity. To reduce false positives and cell line specific 
artefacts, we applied a knockdown approach on the regulatory subunit of PKA, PKA-RIα (20), 
in another breast cancer cell line (MDA-MB134). This may, however, create false negatives 
instead, e.g. by an already activated PKA pathway even before experimental induction. 
Moreover, this approach highlights stable effects, rather than immediate early targets after 
PKA-activation.  Nonetheless, we obtained a set of 100 genes, which could serve as a classifier 
in ERα positive, tamoxifen treated breast cancer. Integration of the PKA-induced 100-gene 
classifier with the chromatin binding landscape of ERαS305-P to extract the direct targets 
for the modified receptor resulted in a list of 26 genes. These 26 targets showed a significant 
correlation with poor disease outcome, suggesting that phosphorylation of ERα plays an 
essential role in tamoxifen response and is not just a bystander effect.
 Studying the 100-gene classifier in more detail, we discovered that MYC-related 
genes were enriched, some of which were identified as direct ERαS305-P targets. In addition, 
the oncogene MYC itself was upregulated. Chapter 4 thus provides a potential functional link 
between ERα phosphorylation and the resulting tamoxifen resistance in breast cancer. This is 
in line with literature correlating the Myc-pathway with tamoxifen resistance in breast cancer 
(21, 22). Moreover, MYC had been described as a direct estrogen-regulated target for ERα and 
hence playing a key role in proliferation of breast cancer cells (22). Here we demonstrate a 
direct link between PKA-induced phosphorylated ERα and MYC in terms of chromatin binding 
landscape, transcriptome and cell proliferation. Taken together, and summarized in Figure 
1, our findings span the entire range from estrogen receptor phosphorylation to tamoxifen 
resistance in molecular terms.
 
 
Figure 1: Schematic summary of Chapter 1, 3 and 4 of this thesis. Estrogen receptor alpha (ERα) 
binds tamoxifen and dimerizes. Depending on the ERαS305 phosphorylation (Ch1) status the 
structural conformation  of the receptor is different, which influences the coregulator recruitment 
(Ch3). Non-phosphorylated ERα still binds to the DNA, as the normal estradiol-bound receptor 
would, but does not induce transcription and thereby blocks tumor cell proliferation in the breast 
cancer patient. ERαS305-P shows enhanced binding of coregulators in the presence of tamoxifen, 
resulting in an enhanced responsive gene activity, including MYC and MYC-related genes, which 
induces cell proliferation and ultimately renders the tumor resistant to tamoxifen.
 Not only do our data provide an understanding into the molecular mechanism of 
tamoxifen resistance through PKA-induced ERαS305 phosphorylation, but also show that 
the effects on gene expression, although dependent on ERαS305 phosphorylation, are not 
tamoxifen specific. Notably, several genes with a proximal binding site for ERαS305 appear to 
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show an additional effect for activated PKA in presence of tamoxifen, as compared to hormone-
depleted conditions, but the molecular mechanism needs further analysis. The presence of 
a PKA-induced effect in absence of tamoxifen implies that the genes in the classifier could 
already be differentially regulated in breast tumors before tamoxifen treatment. The fact that 
our classifier works in two independent patient datasets supports this hypothesis. After all, 
the gene expression data are derived from the primary tumors that have not been exposed to 
tamoxifen. It could therefore prove to be a useful classifier for predicting tamoxifen responses 
in patients before the onset of treatment. A qPCR assay could be developed that assesses 
expression of selected genes, as well as chromatin fragments that are distinctly targeted by 
ERαS305-P. This assay would serve as a prediction tool for tamoxifen responses, in combination 
with the previously reported ERαS305-phospho antibody (18). The immunohistochemical 
staining with this antibody, although successful in a clinical setting, already shows a correlation 
with poor disease outcome when only one nucleus in a tumor slice scores positive (14-16). One 
nucleus in a tumor can be easily missed, but an additional gene classifier may be more sensitive 
to infrequent ERαS305-P tumor cells in tissue and could reduce false negatives. A solid method 
to detect such cells would avoid unnecessary tamoxifen treatment of patients who will not 
benefit from this drug. In addition, the classifier would not be sensitive to dephosphorylation 
events occuring during tissue preparation for immunohistochemistry. An optimal signature 
could include downregulation of PKA-RIα, which has been correlated with PKA activity (and 
ERαS305-P) resulting in tamoxifen resistance (18), as well as MYC and the MYC-related 26-
gene classifier presented in Chapter 4. Combining different approaches should optimize 
prediction of tamoxifen resistance in breast cancer patients by ERαS305 phosphorylation and 
present a way towards personalized medicine for patient treatment with effective compounds 
on rational grounds.
 Efforts are already made to set up a prospective clinical trial for tamoxifen 
resistance by PKA-induced ERαS305 phosphorylation. Patients will be stratified based on 
immunohistochemical staining of tumor tissue with the ERαS305-P recognizing antibody. As 
mentioned earlier, determination of this form of resistance could be fine-tuned by combining 
IHC with gene expression profiling. And since microarrays are routinely performed on breast 
cancer, a gene classifier could easily be integrated in such a clinical trial. When a tumor would 
stain negative for ERαS305-P, the patient would be selected to receive tamoxifen as adjuvant 
treatment after tumor excision, because she is likely to benefit. Patients staining positive 
for this phosphorylation will not receive tamoxifen, but would receive aromatase inhibitors 
instead. Although the optimal setup would be to administer no drugs to the latter group of 
patients, it would be unethical to deny patients any treatment. In a control group, patients will 
be randomized, receiving tamoxifen or aromatase inhibitors, irrespective of their ERαS305-P 
status. We expect that this prospective study will tell us that we can indeed predict (a subset 
of) tamoxifen resistant cases by defining ERαS305-P positivity in breast tumors.
 In summary, phosphorylation of ERα at Serine 305 has major impact on estrogen 
receptor conformation and coregulator binding. One single post-translational modification of 
this receptor, as induced by PKA, redirects its binding positions on the chromatin, which affects 
the transcriptome and thereby induces resistance to tamoxifen. An essential question along 
these lines is: are there treatment alternatives for patients who are defined as non-responders 
to tamoxifen? Previous reports suggest that selective estrogen receptor downregulators 
(SERD), such as fulvestrant, can be effective against cancer cells that have a PKA-induced 
tamoxifen resistance (23, 24). The effect of PKA activation leading to ERαS305 phosphorylation 
on the transcriptome and cell proliferation appears to be independent of ligand (tamoxifen, 
estradiol or no ligand). It would be interesting to test whether a SERD, such as fulvestrant, 
by degrading ERα can inhibit the ER-induced MYC pathway and block cell growth. Another 
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hypothesis that should not be ruled out is that a patient who is resistant to one therapeutic 
may become sensitized to another drug, which would normally be less effective in this type 
of breast cancer. Any form of cancer might become resistant to one therapeutic compound, 
bypassing the targeted molecular pathway and switching to other pathways to evade cell and 
tumor death. These other pathways in turn could be targetable by other drugs, rendering the 
tumor responsive to therapeutics it would normally not respond to. Prostate cancer provides a 
representative example: whereas chemotherapy in the form of taxanes is generally ineffective 
in prostate cancer, a subset of castrate resistant patients suddenly becomes more sensitive to 
this type of treatment (25, 26). A differential regulation of cell cycle pathways lies at the basis 
of this sensitization. In breast cancer, triple negative tumors have been predicted to respond 
much better to chemotherapy than luminal (ER+) breast cancer (27). Along these lines, it 
would be interesting to test whether endocrine resistant tumors, or a subgroup thereof, are 
sensitized to chemotherapy compared to endocrine sensitive breast tumors.
 A challenge for the future would be to map the ERα chromatin binding landscape 
and transcriptome for other post-translational modifications on ERα and to correlate this with 
therapeutic responses to antiestrogens or aromatase inhibitors. Data could be integrated to 
develop new tools that predict response of each individual patient to a range of drugs and 
thereby truly personalize breast cancer treatment. If we can predetermine upon diagnosis to 
which therapy a patient will respond best, we can avoid unnecessary treatment with drugs 
that are not beneficial, and hence also their potential adverse side-effects. Moreover, cancer 
will have less chance to progress by defining the right treatment upfront, instead of the current 
approach, which is largely based on trial and error. Personalization of cancer treatment to the 
individual patient will improve chances of disease-free survival and quality of life of cancer 
patients and this thesis describes how to reach this.
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Nederlandse samenvatting & discussie 
 Wereldwijd worden er jaarlijks 1,4 miljoen nieuwe diagnoses gesteld van borstkanker 
en komen bijna een half miljoen borstkankerpatiënten te overlijden aan de gevolgen van 
borstkanker. Ongeveer 70% van alle gevallen van borstkanker bevatten de oestrogeenreceptor 
en deze tumoren hebben oestrogenen nodig om te groeien. Patiënten met dit type borstkanker 
worden geopereerd en krijgen vaak bestraling. Daarnaast krijgen deze patienten een extra 
behandeling om de kans op uitgroeiende metastasen te verkleinen.  Dit wordt adjuvante 
endocrine (of hormonale) therapie genoemd. Deze hormonale therapie, welke onder te 
verdelen is in twee subklassen van medicijnen: aromataseremmers en anti-oestrogenen. 
Deze twee subklassen verschillen in werkingsmechanismen, maar bereiken hetzelfde effect: 
het blokkeren van de oestrogeenafhankelijke groei van tumorcellen. Aromataseremmers 
voorkomen de synthese van oestrogenen door het verantwoordelijke enzym, aromatase, te 
remmen en ontnemen de oestrogeenreceptor zodanig het natuurlijke ligand (hormoon). Omdat 
de oestrogeen receptor niet geactiveerd kan worden door het natuurlijke ligand, resulteert 
dit in een remming van tumorgroei. Anti-oestrogenen blokkeren de oestrogeenreceptor door 
te binden in de ligandbindende holte, waar normaal gesproken het oestrogeen zou binden. 
Door deze competitie met het natuurlijke ligand om dezelfde bindingsplek kan de oestrogeen 
receptor niet meer binden aan co-acitvatoreiwitten, die essentieel zijn voor de vorming van 
een actief transcriptie complex. Het gevolg van deze remming is dat tumorgroei ook geremd 
wordt.
 Dit proefschrift gaat over het anti-oestrogeen dat het meest wordt toegepast in 
de kliniek, namelijk “tamoxifen”, waarmee veel patiënten reeds succesvol zijn behandeld. 
Echter, niet iedereen heeft baat bij deze vorm van hormoontherapie en zien onverhoopt de 
kanker terugkeren. Het is essentieel om de onderliggende moleculaire biologie van tamoxifen 
resistentie bij borstkanker te bestuderen, opdat we deze kunnen vertalen naar relevante 
toepassingen voor de kliniek, zoals een assay om respons op tamoxifen te kunnen voorspellen 
vóór behandeling.
 Omdat tamoxifen direct op de oestrogeenreceptor werkt, is het belangrijk om de 
functie van dit eiwit te onderzoeken en om te bepalen wat hiermee gebeurt bij resistentie 
tegen het medicijn. In Hoofdstuk 2 hebben we de verschillende subdomeinen waaruit de 
receptor bestaat bestudeerd, daarbij de vraag stellend welke rol(len) deze domeinen spelen 
in de functie van de oestrogeenreceptor na het binden van een ligand. De familie van 
oestrogeenreceptoren bestaat uit twee leden: oestrogeenreceptor alfa (ERα) en beta (ERβ). 
Als een borsttumor positief is voor de oestrogeen receptor, wordt normaliter gerefereerd 
naar het alfa subtype. ERα and ERβ zijn allebei nucleaire receptoren, die na het binden 
van een hormoon aan het DNA binden en bepaalde genen aan kunnen zetten, ook wel 
gentransactivatie genoemd. Ze verschillen echter zowel in klassieke gentransactivatie, waarbij 
de oestrogeenreceptor direct aan het DNA bindt, als in de non-klassieke gentranscactivatie, 
waarbij ze samenwerken met andere transcriptiefactoren. Tevens vertonen ze verschil in 
bindingscapaciteit met cofactoren, hulpeiwitten die oestrogeenreceptor nodig heeft voor 
gentransactivatie. We hebben ERα and ERβ vergeleken om de individuele bijdragen van de 
verschillende domeinen te onderscheiden in hoe de receptor reageert op een ligand. Tussen 
de twee oestrogeenreceptoren is het DNA-bindende domein (DBD) het meest geconserveerd 
(96%). Dit domein kan een interactie aangaan met een oestrogeen responsief element (ERE) 
op het DNA, zodat de receptor vervolgens de expressie van een gen induceren. Het ligand 
bindende domein van beide receptoren is slechts voor 53% geconserveerd, wat zou kunnen 
verklaren dat er specifieke liganden bestaan voor óf ERα óf ERβ. Dit verklaart echter niet 
waardoor ERα en ERβ juist geheel anders kunnen reageren op één en hetzelfde ligand, zoals 
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het geval is voor tamoxifen en oestradiol. In Hoofdstuk 2 laten we zien dat een groot deel van 
deze verschillen worden bepaald door het activatie functie domein 1 (AF-1) en het scharnier 
(hinge) domein, welke grotendeels verschillend zijn tussen ERα and ERβ. We hebben deze 
domeinen uitgewisseld tussen ERα and ERβ, wat de eiwitstructuur beïnvloedde, geobserveerd 
als intramoleculaire fluorescence resonance energy transfer (FRET) veranderingen. Het 
verruilen van het scharnier of het AF-1 domein wisselde in ieder geval deels het specifieke 
gedrag van de oestrogeenreceptor subtypes: de ERα-kenmerkende interactie van het AF-1 
domain met de coregulator SRC-1 en het recruteren van de transcriptie machinerie RNA 
polymerase II (bv. vóór of na ligand binding), waardoor gentransactivatie op het ERE wordt 
beïnvloed. Tevens wordt het effect op gentransactivatie uitgewisseld in een reporter assay 
met een niet-klassiek AP-1 motief. Als de oestrogeenreceptor indirect via andere factoren aan 
dit motief bindt, wordt een eenvoudig te meten reportergen overgeschreven. Het scharnier en 
AF-1 domain lijken in synergie te werken met het activatie functie 2 (AF-2) domein en daarmee 
de functie van de oestrogeenreceptor te bepalen. Desalniettemin blijven sommigen vragen 
onbeantwoord. De ultieme controle voor dit moleculaire mechanisme die nog niet uitgevoerd 
is, is een gecombineerde uitwisseling van zowel het AF-1 en scharnier domain, of als alternatief 
alleen het AF-2 domain, wat in essentie op hetzelfde neerkomt. De verwachte uitkomst van 
deze proef zou een algehele uitwisseling zijn van oestrogeenreceptorfunctie voor de liganden 
die zowel ERα and ERβ kunnen binden. Maar niet voor subtype-specifieke liganden: ERα heeft 
zowel het actieve AF-1 domain als het langere, flexibele scharnier nodig om tot zijn volledige 
oestradiol response te kunnen komen. Het ruilen van een klein deel van het scharnier blijkt 
onvoldoende, ook al is dit deel in ERα hoogst gevoelig voor post-translationele modificaties 
en daarmee een centraal knooppunt voor de functie van de receptor. Deze post-translationele 
modificaties, waaronder de fosforylering van het aminozuur Serine 305, beïnvloeden ERα 
functie, maar niet die van ERβ na het uitwisselen van dit eiwitdeel. Toch detecteren we een 
verandering in structurele conformatie van het eiwit met FRET. Met deze techniek kunnen 
we de orientatie van het AF-1 en AF-2 domein bestuderen door aan de twee uiteinden van 
oestrogeenreceptor een verschillend kleurlabel te hangen: een donor fluorofoor (blauw) en 
een acceptor (geel). Als het donor label met een laser belicht wordt, zendt deze blauw licht uit. 
Als de acceptor echter dichtbij de donor komt door een verandering van eiwitstructuur, kan 
de donor zijn energie overdragen aan de acceptor, die daardoor geel licht af geeft ten koste 
van het blauwe signaal. Als de vouwing van het eiwit verandert, kunnen de labels dichter bij of 
verder van elkaar komen te staan. Een verandering in FRET is zo een maat voor verandering in 
receptorvouwing en op deze wijze hebben wij een verandering in eiwitvouwing gedetecteerd 
bij de uitwisseling van het kleine stukje scharnier domein. Ondanks dat we verschillen meetten 
met FRET, bleek dit zich niet te vertalen in verschillen op gentranscriptie. Dit zou kunnen 
komen doordat de hinge van ERβ korter is en minder flexibel dan die van ERα, wat minder 
ruimte laat om de AF-1 en AF-2 op een juiste manier te plaatsen om coregulators te kunnen 
werven en chromatine te binden. In dit geval blijkt FRET niet indicatief voor downstream 
gentransactivatie.
 De verhouding tussen ERα and ERβ zou bepalend kunnen zijn voor het success 
van endocriene therapie bij borstkanker: ERβ zou oestrogeenafhankelijke groei tegengaan. 
Na het binden van een ligand dimeriseert de oestrogeenreceptor en bindt aan het DNA om 
genexpressie te induceren. Het maakt niet alleen dimeren met zichzelf, c.q. homodimeren 
(ERα:ERα and ERβ:ERβ), maar ook met het andere subtype, heterodimeren (ERα:ERβ). 
Aangezien ERα and ERβ verschillen in functie, zou dit kunnen betekenen dat ook de dimeren 
verschillen in functie. Dit blijkt inderdaad het geval: zowel ERβ homodimeren and ERα:ERβ 
gaan oestradiolafhankelijke groei van borstkankercellen tegen in een experimentele opzet. 
Aangezien het DNA-bindende domein tussen beide oestrogeenreceptoren voor 96% 
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geconserveerd is, zou je verwachten dat beide subtype receptoren op dezelfde plaatsen aan het 
chromatine kunnen binden, en daarmee hetzelfde “chromatine-bindingslandschap” hebben. 
Het zou echter kunnen dat andere eiwitdomeinen buiten het DNA-bindend domein ook een 
rol spelen in het positioneren van de oestrogeenreceptor op het DNA. Een suggestie hiervoor 
is beschreven voor een andere nucleaire receptor, PPAR, dat heterodimeriseert met RXR 
(PPAR:RXR). Het kristalstructuur laat zien dat het C-terminale helix-uiteinde van PPAR langs 
het DNA strekt. Dit zou kunnen betekenen dat de C-terminale helix van de oestrogeenreceptor 
een vergelijkbare synergetische rol samen met het DNA-bindende domein speelt in chromatine 
interactie. Al beschrijft één verhaal dat het chromatine-bindingslandschap overwegend 
gelijk is tussen ERα en ERβ, waarbij ook overlappend genexpressie profiel te verwachten is, 
zou het toch interessant kunnen zijn om alle DNA-interacties in kaart te brengen van de ER 
hetero- en homodimeren middels re-ChIP-seq experimenten om te testen of ze chromatine-
bindingsspecificeit vertonen. Met deze techniek worden chromatinefragmenten in twee 
stappen geïsoleerd: eerst met een antilichaam tegen de ene receptor (c.q. ERα) en vervolgens 
met een antilichaam tegen het tweede (ERβ), opdat slechts de DNA-fragmenten overblijven 
waaraan het heterodimeer bindt. Echter, de oorzaak van de functionele verschillen tussen de 
twee oestrogeenreceptoren lijkt niet te liggen in differentiële DNA interacties, aangezien het 
DNA-bindende domein zeer geconserveerd is. Waarschijnlijker is dat de variaties in AF-1 en 
scharnierdomein de structurele conformatie van de receptor veranderen en zo de binding van 
coregulatoreiwitten beïnvloeden.
 Het recruteren van coregulatoren door de oestrogeenreceptor hebben we bekeken 
in Hoofdstuk 3. Dit is het eerste verhaal, waarin een high-throughput benadering wordt 
toegepast om binding van coregulatoren aan een volledige, endogene oestrogeenreceptor 
te meten. Deze benadering bestaat uit een platform (array), waarop peptidefragmenten 
van coregulatoreiwitten zijn bevestigd. Deze peptides bevatten een motief dat herkend 
en gebonden wordt door nucleaire receptoren: het LxxLL motif. In interactiestudies tussen 
coregulatoreiwitten en de oestrogeenreceptor wordt vaak alleen het ligandbindende domein 
tot overexpressie gebracht. In onze benadering resulteerde een volledige oestrogeen receptor, 
na behandeling met oestradiol, in een peptidebindingsprofiel wat hoogst vergelijkbaar was 
met dat van het ligandbindende domein alleen. Ook blijken verschillen door grote labels, zoals 
de eerder genoemde gele en blauwe fluoroforen, exogene overexpressie of juist endogene 
oestrogeenreceptor verwaarloosbaar voor peptide binding op deze array. Zelfs de celcontekst 
blijkt van weinig invloed op het peptidebindingsprofiel, blijkend uit verwaarloosbare 
verschillen tussen endogeen eiwit in de MCF7 borstkankercellijn en overexpressie in de U2OS 
botkankercellijn. Zoals verwacht hebben liganden impact op cofactorinteracties: oestradiol 
versterkt binding met coregulatoren, terwijl tamoxifen deze interacties juist verzwakt. Na 
het testen van de toepasbaarheid van de peptide array voor oestrogeenreceptorfunctie, 
vroegen we ons af of we hiermee ook tamoxifenresistentie zouden kunnen meten. Eén vorm 
van tamoxifen resistentie werkt via de fosforylering van de oestrogenreceptor op het Serine 
305 (S305) residue door proteïne kinase A (PKA). Deze fosforylering leidt tot een structurele 
verandering van ERα, waarbij de oriëntatie tussen de receptor en de coactivator SRC-1 
verandert, zodat SRC-1 niet alleen aan het AF-1, maar ook aan het AF-2 domain van ERα bindt. 
Dientengevolge wordt het transcriptiecomplex actief, als ERα tamoxifen heeft gebonden. 
De PKA-geïnduceerde conformationele verandering van ERα is mogelijk ook van invloed 
op de oriëntatie en bindingscapaciteit van andere coregulatoren, met als gevolg tevens de 
DNA interacties en genexpressie, wat uiteindelijk kan leiden tot meer celgroei. Op die manier 
kan tamoxifen werken als agonist, in plaats van antagonist, als ERαS305 gefosforyleerd 
is. Zo observeerden we op de peptide array inderdaad sterkere coregulatorbindingen bij 
tamoxifengebonden, S305 gefosforyleerde oestrogenreceptor, wat een meer actieve receptor 
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impliceert in deze tamoxifenresistente setting.
 We detecteerden geen duidelijke coregulatorspecifieke veranderingen. Behandeling 
van de cellen met oestradiol of stimulatie van PKA, waardoor S305 gefosforyleerd wordt, 
resulteerden in een algehele verhoging van coregulatorbinding voor alle peptiden, die voor 
stimulatie al enige interactie vertoonden met ERα ligand. Ook veroorzaakte de verandering 
van receptorconformatie na ligandbinding geen nieuwe interacties met andere peptiden. 
Dit suggereert dat de conformatie op zichzelf niet verantwoordelijk is voor specificiteit in 
interacties met coregulatormotieven, maar dat er andere factoren hierbij een rol lijken te 
spelen. Mogelijkerwijs is het volledige coregulatoreiwit nodig om specificiteit te verkrijgen. 
We weten bijvoorbeeld dat ERα een interactie aangaat met SRC-1 middels zowel het AF-1, als 
het AF-2 domain. Het AF-2 domein bindt het klassieke LxxLL motif, maar het AF-1 herkent een 
aminozuurregio van SRC-1 die rijk is aan glutaminen (Q-rijk domein). Deze tweede interactie 
kan niet gemeten worden in de peptide array, omdat de peptides alleen LxxLL(-achtige) 
motieven bevatten, en geen Q-rijk domein. Bij het ontbreken van een interactie tussen het 
ERα-AF-1 domein het coregulator-Q-rijk domein, welke specificiteit zou kunnen bepalen, 
kan het LxxLL-motif vrij binden na oestradiolbinding meer ruimte begrijp ik niet,,,,, of S305-
fosforylering aan het bindingsoppervlak van het AF-2 domein, zonder sterische hinder van de 
rest van de coregulator. Dit kan wellicht de algeheel versterkte binding op de array zou kunnen 
verklaren.
 Dat neemt niet weg dat de versterkte binding aan LxxLL-coactivatormotieven een 
indicatie is voor verhoogde activiteit van de oestrogeenreceptor. Het is opmerkelijk dat we dit 
effect zelfs kunnen meten met een enkele post-translationele modificatie: S305-fosforylering 
(S305-P). De receptor hoeft niet opgezuiverd te worden uit cellen, wat nogal problematisch 
kan zijn en waarbij een fosforylering makkelijk verloren kan gaan. Zelfs in tumorlysaten is een 
verhoogde ERα functie te detecteren, wanneer S305 gefosforyleerd is, wat in parallel bepaald 
is volgens immunohistochemische analyse. Wel zal een biochemische analyse zoals deze een 
detectielimiet hebben, waaronder het effect van S305-P niet meer te meten is, maar deze moet 
nog bepaald worden. Dientengevolge zal deze benadering niet toepasbaar blijken op tumoren 
met een zeer lage, doch positieve kleuring voor ERαS305-P of als slechts enkele cellen in de 
hele tumor positief zijn. In dat geval wordt het positieve S305-P signal teveel verdund door 
de rest van de tumor. Extraheren van tumorcellen uit het omliggende stroma en de normale 
(niet-tumor) cellen zou de detectie kunnen verbeteren, doordat zo de (gefosforyleerde) 
oestrogeenreceptor geconcentreerd wordt in het tumormonster. Om deze array te kunnen 
gaan toepassen in een klinische setting, moet eerst dit type technische vragen beantwoord 
worden in een uitgebreidere studie.
 Een sterkere binding van ERα uit patiëntenmateriaal aan de peptide array suggereert 
een hogere basale activiteit van de oestrogeenreceptor, welke tamoxifenresistentie zou 
kunnen verklaren. De coregulator peptide array, die ERα meet, zou van toegevoegde waarde 
kunnen zijn in het voorspellen van hoe een patiënt zal reageren op tamoxifenbehandeling. 
Sterkere coregulatorbinding impliceert dat de oestrogeenreceptor gefosforyleerd is en dus 
resistent zal zijn tegen tamoxifen.
 In de kliniek is fosforylering op ERαS305 gecorreleerd met slechter ziekteverloop 
in oestrogeenreceptor-positieve borstkanker bij patienten die met tamoxifen behandeld 
zijn. Een tot nog toe onbeantwoorde vraag is hoe de gefosforyleerde receptor, mogelijk 
via betere binding met coregulatoren, uiteindelijk leidt tot de groei van tumorcellen.  In 
Hoofdstuk 4 hebben wij deze vraag benaderd middels een geïntegreerde analyse van het 
chromatinebindingslandschap en het genexpressieprofiel, of transcriptoom, over het volledige 
genoom van PKA-gefosforyleerd ERα. Deze enkele modificatie heeft een opvallend effect op 
chromatinebinding: normaliter bindt ERα het liefst aan motieven op afstand van genen (distal 
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enhancers), maar ERαS305-P prefereert juist promoter regionen, 5’ en 3’ onvertaalde regionen 
(UTRs) op het DNA, die zich precies aan het begin of eind van genen bevinden. Dit is het eerste 
verslag dat aantoont dat een enkele post-translationele modificatie van ERα grote impact kan 
hebben op het chromatinebindingslandschap van de receptor. Na deze nieuwe ontdekking 
is de vraag onvermijdelijk wat andere post-translationel modificaties van ERα voor effect 
hebben, b.v. fosforylering op andere plekken van de receptor of acetylering. En is dit effect 
vergelijkbaar met wat wij vinden bij ERαS305-P?
 Het transcriptoom is in Hoofdstuk 4 bekeken door PKA-activatie in borstkankercellen. 
MCF7 is een veelgebruikte borstkankercellijn, die we gestimuleerd hebben met een chemische 
stof (forskolin) om PKA te activeren. Om het aantal vals-positieve hits te reduceren hebben 
we daarnaast een benadering toegepast op een andere borstkankercellijn (MDA-MB134), 
waarbij het regulerende subeiwit (PKA-RIα), dat de activiteit van PKA remt, verlaagd 
wordt. Hierdoor kunnen echter meer vals-negatieve hits ontstaan, b.v. doordat het PKA 
signaaltransductienetwerk reeds verhoogde activiteit vertoont vóór het experiment 
gestart wordt. Bovendien laat deze benadering juist stabiele, lange-termijn effecten zien 
van PKA-activatie, en niet zozeer de vroege, tijdelijke effecten. Deze experimentele opzet 
leverde een set van 100 genen op, die als classifier kan worden toegepast op ERα positieve, 
tamoxifenbehandelde borstkanker patiënten. Integratie van deze 100 genen met het 
chromatinebindingslandshap van ERαS305-P om de directe targets voor deze gemodificeerde 
receptor eruit te extraheren, resulteerde in een lijst van 26 genen. Deze 26 targets vertonen 
een significante correlatie met slecht ziekteverloop, wat impliceert dat de fosforylering van 
ERα een essentiële rol speelt in hoe de patiënt reageert op tamoxifen, en dat deze modificatie 
niet enkel een toevallig neveneffect is van PKA-activatie.
 Toen we de 100-genen classifier meer in detail bekeken, ontdekten we dat MYC-
gerelateerde genen verrijkt waren in deze set. MYC is een bekend oncogen, wat cel- en 
tumorgroei bevordert. Sommige van deze genen waren geïdentificeerd als directe ERαS305-P 
targets, omdat de gefosforyleerde receptor op het chromatine in de buurt van deze genen 
bindt. Bovendien was het oncogen MYC zelf ook verhoogd in expressie, zij het net beneden 
de arbitraire drempelwaarde. Hiermee presenteert Hoofdstuk 4 een mogelijke verklaring hoe 
ERα fosforylering kan leiden tot resistentie tegen tamoxifen bij borstkanker, wat verder gaat 
dan enkel een correlatie tussen ERαS305-P en resistentie. Dit past in wat reeds beschreven 
is in de literatuur: MYC-signalering is gecorreleerd met tamoxifenresistentie bij borstkanker. 
Tevens wordt MYC-genexpressie geactiveerd door ERα en speelt zo een sleutelrol in de groei 
van borstkankercellen. Hier tonen wij met chromatinebindings, genexpressie- en celgroei-
experimenten een directe link tussen door PKA gefosforyleerde ERα  en MYC. Samenvattend 
spannen onze bevindingen over het hele traject van oestrogenreceptormodificatie tot en met 
tamoxifenresistentie bij borstkankerpatienten.
 Onze data verklaren niet alleen het moleculaire mechanisme van tamoxifenresistentie 
door PKA-geïnduceerde ERαS305-fosforylering, maar laten ook zien dat PKA ook effect 
heeft op genexpressie in afwezigheid van tamoxifen,. Wel lijken sommmige genen met 
een chromatinebindingsplek voor ERαS305-P een extra effect te vertonen met tamoxifen, 
bovenop wat geactiveerd PKA veroorzaakt bij afwezigheid van hormoon, maar het moleculaire 
mechanisme dat dit veroorzaakt moet nog opgehelderd worden. Het effect van PKA-
activatie in afwezigheid van tamoxifen suggereert dat de genen in de classifier al differentieel 
gereguleerd zouden kunnen zijn in borsttumoren vóór behandeling met tamoxifen. Het feit 
dat de classifier werkt in twee onafhankelijke patientendatasets steunt deze hypothese, 
aangezien de genexpressiedata zijn gegenereerd op primair tumormateriaal wat niet is 
blootgesteld aan tamoxifen. Deze genclassifier zou dus van toegevoegde waarde kunnen 
blijken bij het voorspellen van tamoxifenrespons bij patiënten, voordat de behandeling gestart wordt. 
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Figuur 1: Schematische samenvatting van Hoofdstuk 1,3 en 4 van dit proefschrift. 
Oestrogeenreceptor alpha (ERα) bindt tamoxifen en dimeriseert. De ERαS305 fosforyleringsstatus 
(H1) bepaalt de structurele conformatie van de receptor, wat de binding van coregulatoreiwitten 
beïnvloedt (H3). Niet-gefosforyleerd ERα kan nog steeds aan het DNA binden, zoals een normale, 
oestradiolgebonden receptor, maar induceert geen transcriptie en zo wordt tumorcelgroei 
geblokkeerd. ERαS305-P bindt sterker aan coregulatoren in aanwezigheid van tamoxifen dan een 
niet gefosforyleerde receptor, wat resulteert in verhoogde expressive van specifieke genen (H4). 
Deze genen zijn onder andere MYC and MYC-gerelateerde genen, die celgroei stimuleren en zo de 
tumor resistent maken tegen tamoxifen.
Een qPCR test kan worden ontwikkeld om de expressie van geselecteerde genen te meten, 
gecombineerd met chromatinefragmenten voor specifieke targets van ERαS305-P. Deze test zou 
dan kunnen worden toegepast als predictietool voor tamoxifenrespons, in combinatie met het 
eerder beschreven ERαS305-phospho antilichaam. De immunohistochemische kleuring met dit 
antilichaam, hoewel succesvol in een klinische setting, correleert al met slechter ziekteverloop als 
slechts één celkern positief kleurt in een tumorplakje onder de microscoop. Een enkele celkern 
kan makkelijk over het hoofd worden gezien, maar een goede genclassifier kan wellicht meer 
detecteren als de kleuring niet sterk genoeg is, alsmede vals-negatieven eruit filteren. Een goede 
methode om ERαS305-P positieve tumorcellen te detecteren zou onnodige tamoxifenbehandeling 
van patiënten die hier geen baat bij zullen hebben kunnen voorkomen. Bovendien zou een 
genclassifier, in tegenstelling tot de kleuring, geen last hebben van defosforylering van de 
receptor, wat kan gebeuren bij weefselpreparatie voor immunohistochemie. De optimale 
genexpressieclassifier zou verlaagd PKA-RIα bevatten, wat al gecorreleerd is met PKA-activatie, 
ERαS305-P en tamoxifenresitentie bij borstkankerpatienten, evenals MYC en de MYC-gerelateerde 
26-genen set uit Hoofdstuk 4. Door verschillende benaderingen te combineren kunnen betere 
voorspellingen gedaan worden over tamoxifenresistentie bij borstkankerpatiënten, veroorzaakt 
door ERαS305 fosforylering. Dit is een belangrijke stap naar rationele, persoonsgebonden 
behandeling van patiënten met het juiste, effectieve medicijn.
 Er worden momenteel stappen gezet om een prospectieve, klinische studie te 
starten naar tamoxifenresistentie door PKA-geïnduceerde ERαS305-fosforylering. Patiënten 
zullen in twee groepen verdeeld worden op basis van de immunohistochemische kleuring van 
tumormateriaal met het antilichaam dat ERαS305-P herkent. Zoals eerder aangegeven zou de 
bepaling van deze vorm van resistentie verbeterd kunnen worden door de kleuring te combineren 
met een selectief genexpressieprofiel. Aangezien het in kaart brengen van het transcriptoom 
middels microarrays een routinebepaling is bij borstkanker, zou een genclassifier gemakkelijk 
geïntegreerd kunnen worden in een dergelijke klinische studie. Als een tumor negatief kleurt 
voor ERαS305-P, krijgt de patient tamoxifen voorgeschreven als adjuvante behandeling na het 
verwijderen van de tumor, omdat ze er waarschijnlijk baat bij gaat hebben. Patiënten die positief 
zijn voor deze fosforylering zullen niet behandeld worden met tamoxifen, maar krijgen daarvoor 
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in de plaats aromataseremmers, die mogelijk wel werken. De ideale opzet van deze studie zou 
zijn om de tweede groep een placebo te geven, maar het is onethisch om deze patiënten enige 
behandeling te weigeren. In een controlegroep zullen patiënten gerandomiseerd worden, waarbij 
ze tamoxifen of aromataseremmers ontvangen ongeacht hun ERαS305-P status. We verwachten 
met deze prospectieve studie aan te tonen dat (een deel van de gevallen van) tamoxifenresistentie 
te voorspellen is aan de hand van ERαS305-P positiviteit in borsttumoren.
 Samenvattend heeft fosforylering van ERα op het Serine 305 aminozuur impact 
op oestrogeenreptor-eiwitvouwing en coregulatorbinding. Eén enkele post-translationele 
modificatie, geïnduceerd door PKA, veroorzaakt een relocalisatie van deze receptor op het 
chromatine, wat het transcriptoom verandert en daarmee uiteindelijk ook de respons op 
tamoxifenbehandeling bij een patiënt. Een belangrijke vraag die hierop volgt is: zijn er alternatieven 
voor de behandeling van patiënten die gedefinieerd worden als non-responders op tamoxifen? 
Eerdere publicaties suggereren dat selectieve oestrogeen receptor downregulators (SERD), zoals 
fulvestrant, effectief de oestrogeenreceptoractivatie in kankercellen zouden kunnen remmen, die 
PKA-geïnduceerde resistentie vertonen tegen tamoxifen. Het effect van PKA activatie, wat leidt 
tot ERαS305 fosforylering, op het transcriptoom en celgroei lijkt niet geheel tamoxifenspecifiek 
te zijn, echter voor een deel van de directe gentargets lijkt tamoxifen een additief effect te 
hebben. Het zou interessant kunnen zijn om te testen of een SERD, zoals fulvestrant, door ERα af 
te breken tevens het ER-geïnduceerde MYC netwerk kan blokkeren met als gevolg ook de celgroei 
kan remmen. Een andere hypothese die niet over het hoofd gezien mag worden is dat een patient 
die resistant is tegen één behandeling gevoeliger kan worden voor een andere, welke normaal 
gesproken minder effectief zou zijn bij dit type borstkanker. Kanker, ongeacht welke vorm, 
zou resistant kunnen worden tegen een bepaalde therapie door het ontstaan van een zijspoor 
langs het moleculaire netwerk waarop de therapie gericht is. Zo kunnen de tumorcellen hun 
groei afhankelijk maken van andere netwerken en daarmee cel- en tumorafsterving vermijden. 
Op deze andere netwerken kan echter weer mogelijk worden ingegrepen worden door andere 
medicijnen, waardoor de tumor ineens reageert op een behandeling die normaal gesproken niet 
(goed) werkt. Prostaatkanker is een goed voorbeeld: chemotherapie in de vorm van taxanen is 
normaal gesproken niet effectief in prostaatkanker, maar een subgroup van castratieresistente 
patienten wordt juist meer gevoelig voor dit type therapie. Aan de basis van deze nieuwe 
gevoeligheid ligt een verandering van regulatie in celcyclusnetwerken. Bij borstkanker wordt 
voorspeld dat triple negatieve type borstkanker veel beter zullen reageren op chemotherapie 
dan luminale (ER-positieve) borstkanker. Het zou dan ook interessant kunnen zijn om te testen of 
ER-positieve tumoren, die resistant zijn tegen hormoontherapie, gevoeliger geworden zijn voor 
chemotherapie, in vergelijking met de niet-resistente tumoren.
 Een uitdaging voor de toekomst is om het hele chromatinebindingslandschap en 
transcriptoom voor ERα in kaart te brengen voor andere post-translationele modificaties 
op de receptor en deze te correleren met het wel of niet aanslaan van antioestrogenen en 
aromataseremmers bij patiënten. Het is belangrijk om deze data te integreren, opdat nieuwe 
tools ontwikkeld kunnen worden voor het voorspellen van response van iedere, individuele patiënt 
op verschillende medicijnen en op die manier werkelijk de behandeling tegen borstkanker te 
kunnen personaliseren. Als we bij diagnose direct kunnen bepalen bij welke therapie een patient 
het meeste baat zal hebben, kunnen we onnodige behandeling met medicijnen die niet werken 
voorkomen en daarmee ook eventuele akelige bijwerkingen. Tot nu toe wordt de bepaling veelal 
op basis van trial-and-error bepaald. Door vooraf de juiste behandeling te bepalen, zal kanker 
minder kans krijgen om te ontwikkelen tot een aggressief stadium. Patiëntgerichte behandeling 
van kanker zal de kans op ziektevrije overleving en de kwaliteit van leven van de kankerpatiënt 
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op de afdeling Tumorbiologie aan het Nederlands Kanker Instituut te Amsterdam en werd 
aan het einde begeleid door Prof. Dr. Jacques Neefjes en Dr. Wilbert Zwart. Hier voerde zij 
haar translationele onderzoek uit, dat gericht was op moleculair en cellulair begrip van 
tamoxifen resistentie, met name door fosforylering van het serine 305 aminozuur van de 
oestrogeenreceptor, en de vertaling van ontdekkingen naar de kliniek. Betrokkenheid bij de 
kliniek blijkt tevens uit vrijwilligerswerk in het Antoni van Leeuwenhoek ziekenhuis.
 Na de verdediging van haar proefschrift gaat Renée werken in het lab van Dr. Karen 
Knudsen aan de Thomas Jefferson University, Kimmel Cancer Center in Philadelphia (VS). Daar 
verruilt zij de oestrogeen receptor voor de mannelijke equivalent, de androgeenreceptor, en 
gaat onderzoek doen naar verbetering van therapie voor castratie resistente prostaatkanker.
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